<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1377" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1377/" /><meta name="ncbi_pagename" content="Sickle Cell Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Sickle Cell Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Sickle Cell Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/08/17" /><meta name="citation_author" content="MA Bender" /><meta name="citation_pmid" content="20301551" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1377/" /><meta name="citation_keywords" content="Sickle Cell Disease (Hb S/S)" /><meta name="citation_keywords" content="Sickle-Hemoglobin C Disease (Hb S/C)" /><meta name="citation_keywords" content="Sickle ß-Thalassemia (Hb S/ß+-Thalassemia and Hb S/ß°-Thalassemia)" /><meta name="citation_keywords" content="Hemoglobin subunit beta" /><meta name="citation_keywords" content="HBB" /><meta name="citation_keywords" content="Sickle Cell Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Sickle Cell Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="MA Bender" /><meta name="DC.Date" content="2017/08/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1377/" /><meta name="description" content="Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a &quot;splenic sequestration.&quot; The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Acute chest syndrome is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation. Individuals with the highest rates of hemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers but may be relatively protected from vaso-occlusive pain." /><meta name="og:title" content="Sickle Cell Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a &quot;splenic sequestration.&quot; The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Acute chest syndrome is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation. Individuals with the highest rates of hemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers but may be relatively protected from vaso-occlusive pain." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1377/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/sickle/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1377/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BB8DAE0405E01000000000385014E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1377_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1377_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sft/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rss/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1377_"><span class="title" itemprop="name">Sickle Cell Disease</span></h1><p class="contrib-group"><span itemprop="author">MA Bender</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1377_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1377_ai__"><div class="contrib half_rhythm"><span itemprop="author">MA Bender</span>, MD, PhD<div class="affiliation small">Department of Pediatrics<br />University of Washington<br />Fred Hutchinson Cancer Research Center<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.hctuhderf@rednebm" class="oemail">gro.hctuhderf@rednebm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 15, 2003</span>; Last Update: <span itemprop="dateModified">August 17, 2017</span>.</p><p><em>Estimated reading time: 51 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="sickle.Summary" itemprop="description"><h2 id="_sickle_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Acute chest syndrome is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation. Individuals with the highest rates of hemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers but may be relatively protected from vaso-occlusive pain.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>SCD encompasses a group of disorders characterized by the presence of at least one hemoglobin S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (HbS; p.Glu6Val in <i>HBB</i>) and a second <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in abnormal hemoglobin polymerization. Hb S/S (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> p.Glu6Val in <i>HBB)</i> accounts for 60%-70% of SCD in the United States. Other forms of SCD result from coinheritance of HbS with other abnormal &#x003b2;-globin chain variants, the most common forms being sickle-hemoglobin C disease (Hb S/C) and two types of sickle &#x003b2;-thalassemia (Hb S/&#x003b2;<sup>+</sup>-thalassemia and Hb S/&#x003b2;&#x000b0;-thalassemia); rarer forms result from coinheritance of other Hb variants such as D-Punjab, O-Arab, and E.</p><p>The diagnosis of SCD is established by identification of significant quantities of HbS with or without an additional abnormal &#x003b2;-globin chain variant by hemoglobin assay or by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HBB</i> pathogenic variants where at least one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is the p.Glu6Val <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (e.g., <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> p.Glu6Val; p.Glu6Val and a second <i>HBB</i> pathogenic variant) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>All states in the US have included <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for SCD since 2005. Newborn screening programs perform <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> and/or high-performance liquid chromatography (HPLC) of an eluate of dried blood spots. A few newborn screening programs confirm results with molecular testing.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management of pain episodes includes hydration, anti-inflammatory agents, and pain medication. Pain episodes are additionally managed with a multimodel approach (e.g., warmth, massage, distraction, acupuncture, biofeedback, self-hypnosis). Fever and suspected infection is treated with appropriate antibiotics. Life-threatening or severe complications (e.g., severe acute chest syndrome, aplastic crisis, and stroke) are often treated with red blood cell transfusion. Splenectomy may be necessary for splenic sequestration. Severe priapism may require aspiration and irrigation.</p><p><i>Prevention of primary manifestations:</i> Maintain hydration and avoid climate extremes. Chronic red blood cell transfusion in children at risk for stroke and individuals with pulmonary hypertension, chronic renal failure, recurrent acute chest syndrome, and severe end-organ damage. Hydroxyurea can decrease the frequency and severity of vaso-occlusive processes, reduce transfusion needs, and increase life span. Glutamine has received FDA approval for the prevention of acute complications in individuals with SCD age five years and older. Stem cell transplantation may be an option in selected individuals.</p><p><i>Prevention of secondary complications:</i> Aggressive education on the management of fevers; prophylactic antibiotics, including penicillin in children; immunizations; folic acid supplementation; and iron chelation therapy for those with iron overload.</p><p><i>Surveillance:</i> Periodic comprehensive medical and social evaluation, mental health and neurocognitive assessment, and routine dental care. Annual CBC and reticulocyte count, assessment of iron status, liver and renal function tests, urinalysis, LDH, and vitamin D level. Annual transcranial Doppler to determine risk of stroke in all children with Hb S/S and Hb S/&#x003b2;&#x000b0;-thalassemia and ophthalmologic evaluation in all with sickling disorders. There should be a low threshold to evaluate for end-organ damage including chest x-ray, ECG, abdominal ultrasound, and iron overload. Due to the high frequency and severity of cardiopulmonary complications there should be a particularly low threshold to obtain an echocardiogram, pulmonary function tests, and sleep study in individuals of any age with cardiac or pulmonary concerns.</p><p><i>Agents/circumstances to avoid:</i> Dehydration, extremes of temperature, physical exhaustion, extremely high altitude, recreational drugs with vasoconstrictive or cardiac stimulation effects, and meperidine.</p><p><i>Evaluation of relatives at risk:</i> Early diagnosis of at-risk family members allows education and intervention before symptoms or end-organ damage are present.</p><p><i>Pregnancy management:</i> Women with SCD who become pregnant require close follow up and monitoring by a hematologist and obstetrician; an increased risk for preterm labor, thrombosis, infectious complications, and acute painful episodes has been reported during pregnancy; hydroxyurea should be discontinued during pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SCD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. If one parent is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the <i>HBB</i> HbS <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the other is a carrier of any of the <i>HBB</i> pathogenic variants (e.g., HbS, HbC, &#x003b2;-thalassemia), each child has a 25% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, a 50% chance of being unaffected and a carrier, and a 25% chance of being unaffected and not a carrier. Carrier detection for common forms of SCD is most commonly accomplished by <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> or HPLC. Prenatal diagnosis for pregnancies at increased risk for SCD is possible by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>HBB</i> pathogenic variants have been identified in the parents.</p></div></div><div id="sickle.GeneReview_Scope"><h2 id="_sickle_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="sickle.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sickle.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Included Disorders</th></tr></thead><tbody><tr><td headers="hd_h_sickle.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Homozygous hemoglobin S alleles</div><ul><li class="half_rhythm"><div>Sickle cell disease (Hb S/S)</div></li></ul></li><li class="half_rhythm"><div>Coinheritance of one hemoglobin S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a second HBB <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div><ul><li class="half_rhythm"><div>Sickle-hemoglobin C disease (Hb S/C)</div></li><li class="half_rhythm"><div>Sickle &#x003b2;-thalassemia (Hb S/&#x003b2;+-thalassemia and Hb S/&#x003b2;&#x000b0;-thalassemia)</div></li><li class="half_rhythm"><div>Sickle-hemoglobin D, O, and E disease (or other beta globin chain variants)</div></li></ul></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#sickle.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="sickle.Diagnosis"><h2 id="_sickle_Diagnosis_">Diagnosis</h2><p>The term sickle cell disease (SCD) encompasses a group of disorders characterized by the presence of at least one hemoglobin S <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (HbS; p.Glu6Val in <i>HBB</i>) and a second <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in abnormal hemoglobin polymerization. SCD (Hb S/S) caused by the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>HBB</i> variant p.Glu6Val is the most common cause of SCD in the US. SCD caused by <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>HBB</i> pathogenic variants includes <b>sickle-hemoglobin C disease (Hb S/C)</b> and two types of <b>sickle</b>
<b>&#x003b2;-thalassemia (Hb S/&#x003b2;<sup>+</sup>-thalassemia and Hb S/&#x003b2;&#x000b0;-thalassemia)</b>. Other beta globin chain variants such as D-Punjab, O-Arab, and E also result in SCD when inherited with HbS.</p><div id="sickle.Suggestive_Findings"><h3>Suggestive Findings</h3><p>While there is no single finding suggestive of sickle cell, the presence of the following features should raise suspicion, especially when both clinical and laboratory features are present in a person of Sub-Saharan African, Indian, or Central American descent, or with a family history of SCD.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Infants with spontaneous painful swelling of the hands and feet</div></li><li class="half_rhythm"><div>Recurrent episodes of severe pain with no other identified etiology</div></li><li class="half_rhythm"><div>Unexplained anemia not related to iron deficiency</div></li><li class="half_rhythm"><div>Pallor</div></li><li class="half_rhythm"><div>Jaundice</div></li><li class="half_rhythm"><div>Pneumococcal sepsis or meningitis</div></li><li class="half_rhythm"><div>Severe anemia with splenic enlargement</div></li><li class="half_rhythm"><div>Stroke, especially in a child</div></li></ul><p>Note: Most individuals with SCD are healthy at birth and become symptomatic later in infancy or childhood after fetal hemoglobin levels decrease.</p><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div>Normocytic anemia</div></li><li class="half_rhythm"><div>Sickle cells, nucleated red blood cells, target cells, and other abnormal red blood cells on peripheral blood smear; Howell-Jolly bodies indicate hyposplenism.</div></li><li class="half_rhythm"><div>Presence of hemoglobin S (HbS) on a hemoglobin assay (e.g., high-performance liquid chromatography [HPLC], <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a>, cellulose acetate electrophoresis, citrate agar electrophoresis) with an absence or diminished amount of HbA</div></li></ul><p>(For information about advantages and disadvantages of various hemoglobin assays, click <a href="/books/NBK1377/bin/sickle-hemo_assays.pdf">here</a>.)</p><p><b>Newborn screening.</b> Newborn screening programs perform <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> and/or HPLC of an eluate of dried blood spots. A few <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> programs confirm results with molecular testing.</p><ul><li class="half_rhythm"><div>The normal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> result is "FA" (i.e., more fetal hemoglobin (HbF) compared to adult hemoglobin [HbA]). Note: Hemoglobins identified by newborn screening are reported in order of quantity.</div></li><li class="half_rhythm"><div>Specimens with "FS" are retested using a second confirmatory technique (e.g., HPLC, citrate agar electrophoresis, <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a>, or DNA-based assay [<a href="http://genes-r-us.uthscsa.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">genes-r-us.uthscsa.edu</a>]).</div></li><li class="half_rhythm"><div>Infants with hemoglobins that suggest SCD require additional confirmatory testing of a separate blood sample by age six weeks (see <a class="figpopup" href="/books/NBK1377/table/sickle.T.sickle_cell_disease_diagnostic/?report=objectonly" target="object" rid-figpopup="figsickleTsicklecelldiseasediagnostic" rid-ob="figobsickleTsicklecelldiseasediagnostic">Table 1</a>).</div></li></ul></div><div id="sickle.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SCD is based on the evaluation of adult hemoglobins (HbA, HbS, and other beta globin variants [e.g., HbC, HbE]). Fetal hemoglobin (HbF) is normally the predominant hemoglobin in newborns and decreases over the first year of life.</p><ul><li class="half_rhythm"><div>Identification of HbS as the sole adult beta chain on Hb assay indicates either Hb S/S or Hb S/&#x003b2;&#x000b0;-thalassemia. These can be distinguished by molecular testing, the combination of hemoglobin testing and other clinical studies, or in combination with family history.</div></li><li class="half_rhythm"><div>S/&#x003b2;&#x000b0;-thalassemia and S/&#x003b2;<sup>+</sup>-thalassemia are distinguished by the presence of HbA in individuals with S/&#x003b2;<sup>+</sup>-thalassemia, but HbA is below that observed in sickle cell trait.</div></li><li class="half_rhythm"><div>Identification of HbS and an additional beta-chain variant (e.g., HbC, D, O, or E) on Hb assay can establish the diagnosis in individuals who are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for specific <i>HBB</i> pathogenic variants (e.g., Hb S/C, Hb S/D, Hb S/O, Hb S/E).</div></li></ul><div id="sickle.T.sickle_cell_disease_diagnostic" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Sickle Cell Disease: Diagnostic Test Results</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.T.sickle_cell_disease_diagnostic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.T.sickle_cell_disease_diagnostic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" style="text-align:left;vertical-align:middle;">Abnormal Globin &#x003b2;-Chain Variants&#x000a0;<sup>1</sup></th><th id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_2" style="text-align:left;vertical-align:middle;">Hemoglobins Identified by Age 6 Weeks&#x000a0;<sup>2</sup></th><th id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_3" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Hematologic Studies by Age Two Years</th></tr><tr><th headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4" id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">MCV&#x000a0;<sup>3,&#x000a0;4</sup></th><th headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4" id="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb A<sub>2</sub>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/S (&#x003b2;<sup>S</sup>&#x003b2;<sup>S</sup>)</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">HbF, HbS</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Hemolysis and anemia by age 6-12 months</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;3.6%</td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/&#x003b2;&#x000b0;-thal (&#x003b2;<sup>S</sup>&#x003b2;&#x000b0;)</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;3.6%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/&#x003b2;+-thal (&#x003b2;<sup>S</sup>&#x003b2;<sup>+</sup>)</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbF, HbS, HbA</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Milder hemolysis and anemia</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;<br />N or &#x02193;</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;3.6%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/C (&#x003b2;<sup>S</sup>&#x003b2;<sup>C</sup>)</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbF, HbS, HbC</td><td headers="hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_1_4 hd_h_sickle.T.sickle_cell_disease_diagnostic_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;3.6%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Table shows typical results; exceptions occur. Less common genotypes (e.g., SD, SO<sup>Arab</sup>, SC<sup>Harlem</sup>, Lepore, and E) are not included.</p></div></dd><dt></dt><dd><div><p class="no_margin">thal = thalassemia</p></div></dd><dt></dt><dd><div><p class="no_margin">MCV = mean corpuscular volume</p></div></dd><dt></dt><dd><div><p class="no_margin">N = normal</p></div></dd><dt></dt><dd><div><p class="no_margin">&#x02191; = increased</p></div></dd><dt></dt><dd><div><p class="no_margin">&#x02193; = decreased</p></div></dd><dt>1. </dt><dd><div id="sickle.TF.1.1"><p class="no_margin">The &#x003b2;-thalassemias are divided into &#x003b2;<sup>+</sup>-thalassemia, in which reduced levels of normal &#x003b2;-globin chains are produced, and &#x003b2;&#x000b0;-thalassemia in which there is no &#x003b2;-globin chain synthesis.</p></div></dd><dt>2. </dt><dd><div id="sickle.TF.1.2"><p class="no_margin">Hemoglobins reported in order of quantity (e.g., F, S, A = F&#x0003e;S&#x0003e;A)</p></div></dd><dt>3. </dt><dd><div id="sickle.TF.1.3"><p class="no_margin">Normal MCV: &#x02265;70 at 6-12 months; &#x02265;72 at 1-2 years; &#x02265;81 in adults</p></div></dd><dt>4. </dt><dd><div id="sickle.TF.1.4"><p class="no_margin">Interpretation can be difficult as coexisting iron deficiency and alpha-thalassemia are common in SCD and can also reduce the MCV.</p></div></dd><dt>5. </dt><dd><div id="sickle.TF.1.5"><p class="no_margin">HbA<sub>2</sub> results vary somewhat depending on laboratory method.</p></div></dd><dt>6. </dt><dd><div id="sickle.TF.1.6"><p class="no_margin">HbS with coexistent &#x003b2;-thalassemia causes &#x02193;MCV and often leads to an HbA<sub>2</sub> &#x0003e;3.6%.</p></div></dd></dl></div></div></div><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>HBB</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found on <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>HBB</i> and other genes of interest (see <a href="#sickle.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="sickle.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Sickle Cell Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Alleles with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBB</i></td><td headers="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_sickle.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 6</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sickle.TF.2.1"><p class="no_margin">See <a href="/books/NBK1377/#sickle.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="sickle.TF.2.2"><p class="no_margin">See <a href="#sickle.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="sickle.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="sickle.TF.2.4"><p class="no_margin">Note: All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals would have at least one copy of the <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu6Val</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Targeted assays for p.Glu6Val (HbS), <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu6Lys</a> (HbC), <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu121Gln</a> (HbD), <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu26Lys</a> (HbE), and <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu121Lys</a> (HbO) may be available (see <a href="#sickle.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd><dt>5. </dt><dd><div id="sickle.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used can include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="sickle.TF.2.6"><p class="no_margin">While deletions or duplications will not result in a sickle <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions lead to a thalassemic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> which, if combined with a sickle cell pathogenic variant in <a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> configuration leads to S &#x003b2;&#x000b0;-thalassemia [<a class="bk_pop" href="#sickle.REF.harteveld.2005.922">Harteveld et al 2005</a>].</p></div></dd></dl></div></div></div></div></div><div id="sickle.Clinical_Characteristics"><h2 id="_sickle_Clinical_Characteristics_">Clinical Characteristics</h2><div id="sickle.Clinical_Description"><h3>Clinical Description</h3><p>The clinical manifestations of sickle cell disease (SCD) result from intermittent episodes of microvascular occlusion leading to tissue ischemia/reperfusion injury and chronic hemolysis, both of which contribute to multiorgan dysfunction. The severity of disease manifestations varies, even in individuals with the same <i>HBB</i> pathogenic variants.</p><p><b>Vaso-occlusive events</b> are associated with ischemia/reperfusion damage to tissues that lead to pain and acute or chronic injury affecting any organ system. The bones/marrow, spleen, liver, brain, lungs, kidneys, and joints are often <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. The biologic markers associated with this "vaso-occlusive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>" include the following [<a class="bk_pop" href="#sickle.REF.darbari.2012.286">Darbari et al 2012</a>, <a class="bk_pop" href="#sickle.REF.wood.2012.123ra26">Wood et al 2012</a>]:</p><ul><li class="half_rhythm"><div>A higher WBC count</div></li><li class="half_rhythm"><div>A lower HbF level</div></li><li class="half_rhythm"><div>Older age</div></li><li class="half_rhythm"><div>Coexisting alpha-thalassemia trait</div></li><li class="half_rhythm"><div>Iron overload (secondary to transfusions)</div></li><li class="half_rhythm"><div>Vessel flow resistance related to deoxygenation</div></li></ul><p><b>Chronic hemolysis</b> is associated with chronic anemia as well as vascular dysfunction [<a class="bk_pop" href="#sickle.REF.morris.2011.1">Morris 2011</a>]. Individuals with the highest rates of hemolysis are at increased risk of developing pulmonary artery hypertension, priapism, and leg ulcers [<a class="bk_pop" href="#sickle.REF.kato.2010.690">Kato &#x00026; Taylor 2010</a>]. Biologic markers for this "hemolytic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>" include the following:</p><ul><li class="half_rhythm"><div>Elevated plasma levels of lactate dehydrogenase (LDH)</div></li><li class="half_rhythm"><div>A low hemoglobin level</div></li><li class="half_rhythm"><div>A high reticulocyte count</div></li></ul><p><b>Complications related to vaso-occlusive events</b></p><ul><li class="half_rhythm"><div><b>Vaso-occlusive pain episodes</b> are the most frequent cause of recurrent morbidity in individuals with SCD and account for the majority of SCD-related hospital admissions as well as school and work absences [<a class="bk_pop" href="#sickle.REF.gill.1995.776">Gill et al 1995</a>]. Vaso-occlusion is due to multicellular aggregates that block blood flow in small blood vessels, depriving downstream tissues of nutrients and oxygen, resulting in tissue ischemia and tissue death in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> vascular beds. Vaso-occlusion and ischemic tissue damage cause excruciating pain. Young children more often complain of pain in their extremities, whereas older individuals more commonly experience pain in the head, chest, abdomen, and back.</div></li><li class="half_rhythm"><div><b>Dactylitis</b> (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD and occurs in infants and children. The dorsa of the extremities are most often involved; one or all four extremities can be involved. Although immediate sequelae are rare, dactylitis has been implicated as a risk factor for severe disease [<a class="bk_pop" href="#sickle.REF.miller.2000.83">Miller et al 2000</a>].</div></li><li class="half_rhythm"><div><b>Splenic sequestration and infarction.</b> Splenic sequestration occurs in 10%-30% of children with SCD, most commonly between age six months and three years, and may follow a febrile illness. Splenic sequestration is characterized by an acutely enlarging spleen with hemoglobin &#x0003e;2 g/dL below the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's baseline value. Mild-to-moderate thrombocytopenia may also be present. Children with splenic sequestration may experience abdominal pain, nausea, vomiting, lethargy, or irritability. Blood transfusion may be required as severe splenic sequestration may progress rapidly to shock and death. Recurrent episodes (or difficult-to-manage acute episodes) may require splenectomy. Historically most children with Hb S/S or S/&#x003b2;&#x000b0;-thalassemia will have a dysfunctional spleen within the first year of life and complete auto-infarction and atrophy due to ischemia of the spleen by age five years, though this natural history may be altered by hydroxyurea and chronic transfusion therapy. This splenic dysfunction contributes to the increased risk of sepsis and infection.</div></li><li class="half_rhythm"><div><b>Infection.</b> Young children with SCD and splenic dysfunction are at high risk for septicemia and meningitis due to encapsulated bacteria including <i>Streptococcus pneumonia</i>, <i>Neisseria meningiditis</i>, and <i>Haemophilus influenza</i>. Vaccination programs and prophylactic penicillin have significantly decreased the incidence of these infections [<a class="bk_pop" href="#sickle.REF.adamkiewicz.2003.438">Adamkiewicz et al 2003</a>].</div></li><li class="half_rhythm"><div>Individuals with SCD are also at increased risk for other infections such as osteomyelitis caused by <i>Staphylococcus aureus</i> or other organisms such as <i>Salmonella</i> species. Infectious agents implicated in acute chest syndrome include <i>Mycoplasma pneumoniae</i>, <i>Chlamydia</i>
<i>pneumoniae</i>, and <i>Streptococcus</i>
<i>pneumonia</i>, as well as viruses. Parvovirus remains an important cause of aplastic crisis. Indwelling central venous catheters confer a high risk of bacteremia in individuals with SCD [<a class="bk_pop" href="#sickle.REF.chulamokha.2006.723">Chulamokha et al 2006</a>, <a class="bk_pop" href="#sickle.REF.zarrouk.2006.43">Zarrouk et al 2006</a>].</div></li><li class="half_rhythm"><div><b>Acute chest syndrome (ACS)</b> is a complex process that can arise from multiple diverse etiologies. ACS is a major cause of mortality [<a class="bk_pop" href="#sickle.REF.bakanay.2005.545">Bakanay et al 2005</a>]. Although the definition varies in the literature, the diagnosis typically is made by the presence of a new pulmonary infiltrate on chest radiography in a person with SCD. This is often in the presence of respiratory tract symptoms, chest pain, hypoxemia, and/or fever. ACS often develops in the setting of a vaso-occlusive episode or with other acute manifestations of SCD, frequently after two to three days of severe vaso-occlusive pain. ACS can progress rapidly (over several hours to days) to requiring intubation and mechanical ventilatory support. A high index of suspicion is indicated: the presenting signs and symptoms of ACS can be highly variable and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have an initial normal physical examination [<a class="bk_pop" href="#sickle.REF.morris.1999.64">Morris et al 1999</a>]. Multiple etiologies (e.g., fat emboli from bone marrow infarcts, pneumonia, pulmonary infarction, pulmonary embolus), often at the same time, can lead to acute chest syndrome [<a class="bk_pop" href="#sickle.REF.mekontso_dessap.2011.1022">Mekontso Dessap et al 2011</a>].</div></li></ul><p><b>Neurologic complications</b> in SCD include stroke, silent cerebral infarcts, cerebral hemorrhage, cerebral blood flow abnormalities including Moyamoya disease, and cerebral microvascular disease. Up to 50% of individuals with SCD will manifest some degree of cerebrovascular disease by age 14 years [<a class="bk_pop" href="#sickle.REF.bernaudin.2011.1130">Bernaudin et al 2011</a>].</p><ul><li class="half_rhythm"><div><b>Ischemic strokes,</b> most often seen in children and older adults, are among the most catastrophic manifestations of SCD. Common presenting signs and symptoms include: hemiparesis, monoparesis, seizures, aphasia or dysphasia, cranial nerve palsies, and mental status changes. Overt strokes occur in as many as 11% of children with SCD, with the peak occurrence between ages two and nine years. Recurring strokes occur in 50%-70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals within three years after the first event. Transfusion therapy instituted after the initial stroke significantly reduces this risk [<a class="bk_pop" href="#sickle.REF.serjeant.2013.a011783">Serjeant 2013</a>]. Narrowing of cerebral vessels is a risk factor for stroke, and elevated flow velocity on transcranial Doppler (TCD) identifies most children at high risk [<a class="bk_pop" href="#sickle.REF.adams.1998.5">Adams et al 1998</a>], allowing intervention prior to the development of stroke [<a class="bk_pop" href="#sickle.REF.debaun.2016.829">DeBaun &#x00026; Kirkham 2016</a>].</div></li><li class="half_rhythm"><div><b>Silent cerebral infarcts</b> (SCI) occur in approximately 22%-35% of individuals with SCD [<a class="bk_pop" href="#sickle.REF.bernaudin.2011.1130">Bernaudin et al 2011</a>]. Silent cerebral infarcts are lesions identified on cerebral imaging studies without known focal neurologic symptoms; however, such lesions may be associated with neurocognitive deficits [<a class="bk_pop" href="#sickle.REF.schatz.2001.1109">Schatz et al 2001</a>] and an increased risk for overt stroke [<a class="bk_pop" href="#sickle.REF.miller.2001.785">Miller et al 2001</a>]. Thus, a "silent infarct" should not be thought of as a clinically insignificant condition. Cerebral arterial stenosis is noted to be a risk factor for SCI but is not always reflected by increased TCD velocities due to multiple variables, which influence individual vessel velocities. Additionally, accuracy of TCD measurements in demonstrating intracranial stenosis has not been firmly established. Utilization of methods to identify increased risk of stroke due to SCI, such as MRI/MRA, are being studied [<a class="bk_pop" href="#sickle.REF.arkuszewski.2014.108">Arkuszewski et al 2014</a>, <a class="bk_pop" href="#sickle.REF.debaun.2016.829">DeBaun &#x00026; Kirkham 2016</a>].</div></li></ul><p><b>Complications related to hemolysis.</b> A hyper-hemolysis syndrome marked by an elevated LDH, low hemoglobin level, and low reticulocyte count is associated with leg ulcers, priapism, pulmonary artery hypertension, systemic hypertension, and platelet activation [<a class="bk_pop" href="#sickle.REF.hebbel.2011.123">Hebbel 2011</a>]. Other consequences of hemolysis include: chronic anemia, jaundice, predisposition to aplastic crisis, and cholelithiasis. While those with the highest rates of hemolysis may experience fewer pain episodes, the overall mortality rate for this group of individuals may be higher [<a class="bk_pop" href="#sickle.REF.hebbel.2011.123">Hebbel 2011</a>, <a class="bk_pop" href="#sickle.REF.kato.2017.750">Kato et al 2017</a>].</p><p><b>Aplastic crisis</b> is the temporary interruption of red blood cell production, typically due to human parvovirus B19 infection in children, resulting in an acute and potentially life-threatening anemia. Sickle red blood cells survive for only about seven to 12 days, compared to 100-120 days for normal red blood cells. Thus parvovirus B19 infection, which can interrupt red blood cell production for eight to ten days, can result in a drop of hemoglobin level of 1 g/dL per day, leading to life-threatening levels in individuals with SCD that may require red blood cell transfusion.</p><p><b>Pulmonary hypertension.</b> Pulmonary artery hypertension (PAH) affects approximately 6%-35% of adults with SCD and can have profound consequences [<a class="bk_pop" href="#sickle.REF.parent.2011.44">Parent et al 2011</a>]. Although a similar proportion of children with SCD have PAH as diagnosed by echocardiography, PAH does not appear to be associated with the same dire outcomes as in adults [<a class="bk_pop" href="#sickle.REF.lee.2009.437">Lee et al 2009</a>, <a class="bk_pop" href="#sickle.REF.liem.2009.645">Liem et al 2009</a>, <a class="bk_pop" href="#sickle.REF.hebson.2015.134">Hebson et al 2015</a>].</p><p>While many have defined PAH in SCD by an elevated tricuspid regurgitant jet velocity (TRV) on transthoracic echocardiography (TTE), subsequent studies using direct measurement of PAP (pulmonary arterial pressure) by right heart catheterization indicate that this may over-diagnose PAH [<a class="bk_pop" href="#sickle.REF.parent.2011.44">Parent et al 2011</a>]. PAH in adults is associated with markedly increased mortality [<a class="bk_pop" href="#sickle.REF.de_castro.2008.19">De Castro et al 2008</a>] and significant morbidity, including exercise intolerance [<a class="bk_pop" href="#sickle.REF.sachdev.2011.1452">Sachdev et al 2011</a>]. Risk factors for PAH include markers of increased hemolysis, such as elevated LDH [<a class="bk_pop" href="#sickle.REF.kato.2006.2279">Kato et al 2006</a>], markers of cardiac strain, such as elevated brain natriuretic peptide (BNP) [<a class="bk_pop" href="#sickle.REF.machado.2006.310">Machado et al 2006</a>], and the presence of obstructive sleep apnea [<a class="bk_pop" href="#sickle.REF.hebson.2015.134">Hebson et al 2015</a>]. Some individuals are relatively asymptomatic in the early stages of PAH. The relevance of these factors in children is less clear.</p><p><b>Priapism</b> is very common among males with SCD, with a mean age of onset of 15 years [<a class="bk_pop" href="#sickle.REF.adeyoju.2002.898">Adeyoju et al 2002</a>]. These painful, unwanted erections occur spontaneously, with nocturnal erections, or with fever and dehydration. Males may have episodes of stuttering (intermittent) priapism lasting fewer than two to four hours that are often recurrent and may precede a more severe and persistent episode. "Severe priapism" episodes are persistent; those lasting more than two to four hours need rapid intervention because prolonged priapism may result in permanent erectile tissue damage and impotence [<a class="bk_pop" href="#sickle.REF.rogers.2005.917">Rogers 2005</a>].</p><p><b>Other complications</b> of SCD include: avascular necrosis (typically involving the femoral head or humerus), nephropathy, restrictive lung disease, cholelithiasis, retinopathy, cardiomyopathy, and delayed growth and sexual maturation. Individuals with hemoglobin SC disease are at particularly high risk for retinopathy [<a class="bk_pop" href="#sickle.REF.powars.2002.206">Powars et al 2002</a>]. Cardiopulmonary complications represent a major mortality risk in adults [<a class="bk_pop" href="#sickle.REF.fitzhugh.2010.36">Fitzhugh et al 2010</a>].</p><p>Individuals who receive frequent red blood cell transfusion can develop problems with iron overload, with tissue iron deposition potentially damaging the liver, lungs, and heart [<a class="bk_pop" href="#sickle.REF.kushner.2001.47">Kushner et al 2001</a>], and alloimmunization that may interfere with the ability to obtain fully matched units of blood for transfusion [<a class="bk_pop" href="#sickle.REF.vichinsky.1990.1617">Vichinsky et al 1990</a>].</p><p><b>Life expectancy.</b> Previously, median survival in the US for those with SCD was estimated at age 42 years for men and age 48 years for women [<a class="bk_pop" href="#sickle.REF.platt.1994.1639">Platt et al 1994</a>]; however, survival of a subset of individuals with SCD beyond age 55 or 60 years has been described, though morbidity remains high [<a class="bk_pop" href="#sickle.REF.serjeant.2013.a011783">Serjeant 2013</a>]. In addition, some evidence shows a shift towards longer survival over the last 20 years, with a significant decrease in childhood deaths [<a class="bk_pop" href="#sickle.REF.hassell.2010.s512">Hassell 2010</a>, <a class="bk_pop" href="#sickle.REF.quinn.2010.3447">Quinn et al 2010</a>].</p><p>The main causes of death are infection, acute chest syndrome, pulmonary artery hypertension, and cerebrovascular events [<a class="bk_pop" href="#sickle.REF.bakanay.2005.545">Bakanay et al 2005</a>]. Causes of death in children tend to differ from those in adults. Children have higher rates of death from infection and sequestration crises whereas adult mortality is secondary to chronic end-organ dysfunction, thrombotic disease, and treatment-related complications [<a class="bk_pop" href="#sickle.REF.manci.2003.359">Manci et al 2003</a>].</p><p><b>Heterozygotes for HbS</b> have hemoglobins A and S (Hb A/S) (also called <b>sickle cell trait</b>). Heterozygous individuals are not anemic and have normal red cell indices with hemoglobin S percentages typically near 40%. In regions of the world where malaria is endemic, Hb A/S confers a survival advantage in childhood malaria; this is thought to be a major selective pressure for persistence of the HbS <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (<a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu6Val</a>).</p><p>The amount of HbS present is insufficient to produce sickling manifestations under most circumstances and, thus, these individuals are usually asymptomatic but are at risk for several complications [<a class="bk_pop" href="#sickle.REF.key.2010.418">Key &#x00026; Derebail 2010</a>]:</p><ul><li class="half_rhythm"><div>Extremes of physical exertion, dehydration, and/or altitude can induce sickle cell vaso-occlusive events in some individuals with Hb A/S [<a class="bk_pop" href="#sickle.REF.mitchell.2007.300">Mitchell 2007</a>]. Individuals with Hb A/S should maintain aggressive hydration during extreme physical exertion, with no formal activity restrictions recommended. There is increased awareness of the low but significant risks for pulmonary emboli, exertional rhabdomyolysis, and sudden death with extreme exertion in individuals with Hb A/S. This has led to the mandatory offering of testing to all NCAA Division I college athletes [<a class="bk_pop" href="#sickle.REF.bonham.2010.997">Bonham et al 2010</a>]. The full implications of this policy are unclear, and the role of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> in this setting is complex as there is debate about the impact and consequences of testing [<a class="bk_pop" href="#sickle.REF.aloe.2011.337">Aloe et al 2011</a>, <a class="bk_pop" href="#sickle.REF.tarini.2012.446">Tarini et al 2012</a>, <a class="bk_pop" href="#sickle.REF.thompson.2013">Thompson 2013</a>].</div></li><li class="half_rhythm"><div>Splenic infarct at high altitudes, impaired renal concentrating abilities, and intermittent micro- and macroscopic hematuria can occur in some individuals with Hb A/S.</div></li><li class="half_rhythm"><div>Renal medullary carcinoma is an extremely rare form of kidney cancer occurring almost exclusively in individuals with sickle cell trait [<a class="bk_pop" href="#sickle.REF.goldsmith.2012.340">Goldsmith et al 2012</a>] such that a high index of suspicion for this rare diagnosis should be given for individuals with sickle cell trait who present with hematuria.</div></li><li class="half_rhythm"><div>HB A/S may be associated with an increased risk for venous thromboembolism [<a class="bk_pop" href="#sickle.REF.austin.2007.908">Austin et al 2007</a>].</div></li><li class="half_rhythm"><div>There has not been an association of sickle cell trait with avascular necrosis, stroke, leg ulcers, cholelithiasis, or end-stage renal disease [<a class="bk_pop" href="#sickle.REF.goldsmith.2012.340">Goldsmith et al 2012</a>, <a class="bk_pop" href="#sickle.REF.naik.2017.2180">Naik et al 2017</a>].</div></li></ul></div><div id="sickle.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Although a tremendous amount of individual variability occurs, individuals with Hb S/S and S/&#x003b2;&#x000b0;-thalassemia are generally more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than individuals with Hb S/C or S/&#x003b2;<sup>+</sup>-thalassemia. Molecular and genetic factors that are responsible for this variability are being investigated [<a class="bk_pop" href="#sickle.REF.steinberg.2006.131">Steinberg &#x00026; Adewoye 2006</a>].</p><p>Individuals with Hb S/C have longer red cell life span and higher hemoglobin concentration associated with fewer vaso-occlusive pain episodes. Splenomegaly and the associated risk for splenic sequestration can persist well beyond early childhood. Proliferative retinopathy and avascular necrosis are more likely to develop than in those with other sickle hemoglobinopathies.</p><p>The presence of <a href="/books/n/gene/a-thal/">&#x003b1;-thalassemia</a> may modify SCD severity (see <a href="#sickle.Differential_Diagnosis">Differential Diagnosis</a>). In general, &#x003b1;-thalassemia improves red cell survival and decreases hemolysis in SCD. However, the clinical effect on SCD is unclear and can be variable including possible decreased complications arising from hemolysis and potentially increased complications from vaso-occlusive events [<a class="bk_pop" href="#sickle.REF.steinberg.2005.465">Steinberg 2005</a>].</p></div><div id="sickle.Nomenclature"><h3>Nomenclature</h3><p>Historically in the US, the term "sickle cell anemia" was used to describe persons <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for HbS. With increased awareness of the broad spectrum of clinically significant sickle hemoglobinopathies with varying degrees of anemia, the trend has been to use the umbrella term "sickle cell disease." The term sickle cell disease should be followed by a detailed genotypic description for the individual (e.g., Hb S/S, Hb S/C, or S/&#x003b2;&#x000b0;-thalassemia).</p></div><div id="sickle.Prevalence"><h3>Prevalence</h3><p>The HbS <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is common in persons of African, Mediterranean, Middle Eastern, and Indian ancestry and in persons from the Caribbean and parts of Central and South America, but can be found in individuals of any ethnic background.</p><p>Among African Americans, the prevalence of sickle cell trait (Hb A/S) is about 10%, resulting in the birth of approximately 1100 infants with SCD (Hb S/S) annually in the US. Approximately one in every 300-500 African Americans born in the US has SCD; more than 100,000 individuals are estimated to have SCD (Hb S/S) [<a class="bk_pop" href="#sickle.REF.hassell.2010.s512">Hassell 2010</a>].</p><p>The prevalence of <i>HBB</i> alleles associated with SCD is even higher in other parts of the world. In many regions of Africa, the prevalence of the HbS <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (<a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">p.Glu6Val</a>) is as high as 25%-35%, with an estimated 15 million Africans <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by SCD and 200-300,000 affected births per year worldwide [<a class="bk_pop" href="#sickle.REF.aliyu.2008.63">Aliyu et al 2008</a>, <a class="bk_pop" href="#sickle.REF.mousa.2010.291">Mousa &#x00026; Qari 2010</a>]. SCD accounts for as many as 16% of deaths of children younger than age five years in Western Africa [<a class="bk_pop" href="#sickle.REF.neville.2011">Neville &#x00026; Panepinto 2011</a>].</p></div></div><div id="sickle.Genetically_Related_Allelic_Disor"><h2 id="_sickle_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p><a href="/books/n/gene/b-thal/"><b>&#x003b2;-thalassemia</b></a> is defined by an imbalance of &#x003b1;- and &#x003b2;-globin synthesis. Most commonly this is caused by <i>HBB</i> pathogenic variants that result in decreased or absent production of &#x003b2;-globin (hemoglobin A), although this can also occur with excessive &#x003b1;-chain production (see <a href="#sickle.Differential_Diagnosis">Differential Diagnosis</a>), as with the presence of triplicated &#x003b1;-globin genes. More than 200 different &#x003b2;-thalassemia pathogenic variants have been described.</p></div><div id="sickle.Differential_Diagnosis"><h2 id="_sickle_Differential_Diagnosis_">Differential Diagnosis</h2><p>The following diagnoses may be considered in an individual presenting with clinical features of SCD who did not have access to <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>. Each of these conditions would be easily distinguished from SCD by the absence of HbS on hemoglobin assay:</p><ul><li class="half_rhythm"><div>Acute anemia</div></li><li class="half_rhythm"><div>Hemolytic anemia</div></li><li class="half_rhythm"><div>Legg-Calve-Perthes disease</div></li><li class="half_rhythm"><div>Osteomyelitis</div></li><li class="half_rhythm"><div>Septic arthritis</div></li></ul></div><div id="sickle.Management"><h2 id="_sickle_Management_">Management</h2><div id="sickle.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of end-organ damage and needs in an individual diagnosed with sickle cell disease (SCD), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Hematology consultation</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Additional evaluations vary with the age and clinical status of the individual:</p><ul><li class="half_rhythm"><div><b>Infants</b>
<b>after 12 months</b> should have baseline laboratory studies including the following:</div><ul><li class="half_rhythm"><div>CBC and reticulocyte count</div></li><li class="half_rhythm"><div>Measurement of HbF (%)</div></li><li class="half_rhythm"><div>Assessment of iron status</div></li><li class="half_rhythm"><div>A thalassemia screen, which includes hemoglobin electrophoresis or HPLC and an inclusion body prep</div></li><li class="half_rhythm"><div>Baseline vitamin D; renal and liver function tests</div></li><li class="half_rhythm"><div>Extended red cell phenotyping so that antigen matched blood may be given if transfusion is urgently needed</div></li></ul></li><li class="half_rhythm"><div><b>During childhood</b> HLA typing should be offered to the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and all full biologically matched sibs.</div></li><li class="half_rhythm"><div><b>Older individuals.</b> See <a href="#sickle.Surveillance">Surveillance</a>.</div></li></ul></div><div id="sickle.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Lifelong comprehensive care</b> is necessary to minimize morbidity, reduce early mortality, and maximize quality of life. See <a href="#sickle.References">Published Guidelines/Consensus Statements</a>.</p><p><b>Education</b> of parents, caregivers, and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals is the cornerstone of care:</p><ul><li class="half_rhythm"><div>Families must appreciate the importance of routine health maintenance visits, prophylactic medications, and early intervention for both acute and chronic complications.</div></li><li class="half_rhythm"><div>Warning signs of acute illness such as fever, respiratory symptoms, pallor, lethargy, splenic enlargement, and neurologic changes must be reviewed regularly and must include education for the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, as developmentally appropriate.</div></li><li class="half_rhythm"><div>A systematic approach to pain management should be reviewed regularly. This includes identifying and reversing common triggers for sickle cell pain (and distinguishing it from other etiologies of pain), hydration, warmth, ambulation, distraction, and other comfort maneuvers. Initiation of NSAIDs and appropriate use of opiates should be reviewed.</div></li><li class="half_rhythm"><div>All families should have a plan in place for 24-hour access to a medical facility that can provide urgent evaluation and treatment of acute illnesses such as fever, acute chest syndrome, splenic sequestration, and stroke.</div></li><li class="half_rhythm"><div>Families should be provided baseline (steady state) laboratory values for purposes of comparison, as values often change during acute illness.</div></li></ul><p><b>General management of specific problems</b> [<a class="bk_pop" href="#sickle.REF94">NHS 2010</a>, <a class="bk_pop" href="#sickle.REF.bender.2012">Bender &#x00026; Seibel 2012</a>, <a class="bk_pop" href="#sickle.REF.brousse.2014.g1765">Brousse et al 2014</a>, <a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>] includes the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Vaso-occlusive pain episodes</b> (including dactylitis)</div><ul><li class="half_rhythm"><div>The initial focus should include the reversal of inciting triggers (e.g., cold, dehydration).</div></li><li class="half_rhythm"><div>Pain episodes are optimally managed using a multimodel approach that may include warmth, hydration, massage, distraction, acupuncture, biofeedback, self-hypnosis, and pharmaceuticals.</div></li><li class="half_rhythm"><div>Uncomplicated pain episodes may be managed at home with oral hydration and oral analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs) and opiates.</div></li><li class="half_rhythm"><div>More severe pain episodes require hospitalization and administration of parenteral fluids and analgesics in addition to adjunctive treatments such as massage and physical therapy.</div></li><li class="half_rhythm"><div>Optimal analgesia is generally achieved with morphine (or other opiate) given around the clock by a patient-controlled analgesia device (PCA) or by continuous infusion.</div></li><li class="half_rhythm"><div>NSAIDs (e.g., ketorolac, ibuprofen, naproxen) may be used to augment the analgesic effect of opiates. NSAIDs can also decrease inflammation, which is part of the pathophysiology.</div></li><li class="half_rhythm"><div>Adequate but not excessive hydration with IV fluids should be provided to maintain euvolemia, and individuals should be monitored closely for the development of other complications such as acute chest syndrome (ACS), splenic sequestration, or opiate-induced constipation.</div></li><li class="half_rhythm"><div>A thorough evaluation for infection, including blood culture, urine culture, and chest x-ray should be considered based on the clinical scenario.</div></li></ul><div class="half_rhythm">Note: Transfusion and hydroxyurea are not useful treatments for acute pain episodes (see <a href="#sickle.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Fever/suspected infection.</b> Individuals with temperature greater than 38.3&#x000b0; C or persistent temperature elevation above baseline require:</div><ul><li class="half_rhythm"><div>Rapid triage and physical assessment;</div></li><li class="half_rhythm"><div>Urgent CBC and reticulocyte count;</div></li><li class="half_rhythm"><div>Blood culture (and other cultures as clinically indicated) and a low threshold for chest x-ray when respiratory symptoms are present, as ACS can often present with a normal physical examination;</div></li><li class="half_rhythm"><div>Parenteral broad-spectrum empiric antibiotics such as ceftriaxone pending culture results. A macrolide antibiotic should be added if pneumonia/ACS is a concern. Additional antibiotics should be added only for proven or suspected meningitis or other severe illness.</div></li></ul><div class="half_rhythm">Note: With the changing natural history of fever and sepsis in individuals with SCD in the US there is increasing evidence that empiric treatment with parenteral antibiotics without obtaining cultures may be appropriate for well-appearing, fully immunized children with fever &#x0003c;39 C; however, this work has not yet been replicated nor has it become accepted practice [<a class="bk_pop" href="#sickle.REF.baskin.2013.1035">Baskin et al 2013</a>, <a class="bk_pop" href="#sickle.REF.ellison.2015.423">Ellison et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Acute chest syndrome (ACS).</b> The index of suspicion for ACS should be high when individuals with SCD have fever, chest pain, or respiratory signs or symptoms. Given the high mortality associated with ACS, an aggressive multimodal treatment strategy should be initiated [<a class="bk_pop" href="#sickle.REF.miller.2011.5297">Miller 2011</a>]:</div><ul><li class="half_rhythm"><div>Perform chest x-ray examination.</div></li><li class="half_rhythm"><div>Provide aggressive treatment with oxygen, analgesics, and antibiotics (including a macrolide).</div></li><li class="half_rhythm"><div>Incentive spirometry should be encouraged.</div></li><li class="half_rhythm"><div>Hypoxemia can progress to need for intubation and mechanical ventilatory support.</div></li><li class="half_rhythm"><div>Blood transfusion may be required for those who are critically ill, have multilobar disease, or have progressive disease despite conservative therapy.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Aplastic crisis.</b> Monitoring of hematocrit (both absolute and compared with the individual's baseline), reticulocyte count, and cardiovascular status are required. Blood transfusion may be necessary. Aplastic crisis caused by parvovirus B19 will often spontaneously resolve; however, if the reticulocyte count does not improve, intravenous gamma-globulin can be considered to assist in viral clearance. Any sibs or other close contacts with SCD should be monitored for red blood cell aplasia because the parvovirus is easily transmissible.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Splenic sequestration.</b> Severe episodes of splenic sequestration may progress rapidly to cardiovascular collapse and death; thus, emergency red blood cell transfusion is indicated when signs of cardiovascular instability are present. Parents should be taught how to monitor for splenic enlargement and recognize symptoms of sequestration and when to seek medical attention. Individuals who experience multiple severe episodes of splenic sequestration may require splenectomy.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Pulmonary hypertension.</b> Diagnostic criteria, as well as when and how to intervene, are becoming increasingly controversial [<a class="bk_pop" href="#sickle.REF.hassell.2014.237">Hassell et al 2014</a>, <a class="bk_pop" href="#sickle.REF.klings.2014a.238">Klings et al 2014a</a>, <a class="bk_pop" href="#sickle.REF.klings.2014b.2881">Klings et al 2014b</a>, <a class="bk_pop" href="#sickle.REF.hebson.2015.134">Hebson et al 2015</a>]. Existing consensus guidelines are not fully accepted by experts in the field. Thus, discussion with local sickle cell and pulmonary hypertension experts should be used to guide care. The following general approach is reasonable:</div><ul><li class="half_rhythm"><div>Aggressive evaluation and treatment of additional etiologies contributing to pulmonary hypertension (e.g., thrombotic disease, obstructive sleep apnea)</div></li><li class="half_rhythm"><div>Optimization of SCD-related therapy to stop progression (e.g., chronic transfusions, hydroxyurea, oxygen therapy if hypoxemic)</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Stroke.</b> Any history of an acute neurologic symptom or event warrants emergent evaluation including a CBC with reticulocyte count and a non-contrast brain CT examination. Cerebral hemorrhage requires immediate neurosurgical consultation. An MRI/MRA to define injury should be obtained as soon as available, but definitive treatment with exchange transfusion should never be delayed for these results.</div><div class="half_rhythm">Treatment for children with acute ischemic stroke includes the following:</div><ul><li class="half_rhythm"><div class="half_rhythm">Monitor neurologic status and aggressively treat increased intracranial pressure and seizures, if present.</div></li><li class="half_rhythm"><div class="half_rhythm">Exchange transfusion with the goal of decreasing HbS percentage to &#x0003c;30% of the total hemoglobin followed by a chronic transfusion program can significantly decrease repeat risk for stroke [<a class="bk_pop" href="#sickle.REF.wang.2000.335">Wang et al 2000</a>]. Without continued therapy, as many as 60%-90% of individuals who have had a stroke have a second stroke within three years. Thus, in most individuals a preventive chronic transfusion protocol is initiated after a CNS event and continued indefinitely [<a class="bk_pop" href="#sickle.REF.adams.2005.2769">Adams &#x00026; Brambilla 2005</a>] (see <a href="#sickle.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">Hydroxyurea has been studied as an alternative to transfusion therapy [<a class="bk_pop" href="#sickle.REF.ware.2012.3925">Ware &#x00026; Helms 2012</a>]. While it does not provide the same protection as transfusion therapy, it may be an alternative for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who are unable to receive transfusion therapy (e.g., those living in limiting resource settings such as the Third World) or are difficult to transfuse due to alloimmunization [<a class="bk_pop" href="#sickle.REF.de_montalembert.2012.3870">de Montalembert 2012</a>].</div><div class="half_rhythm">Chronic transfusion has been shown to reduce silent infarcts; however, unlike for overt infracts, there is not a universally accepted consensus regarding the management of individuals with silent infarcts [<a class="bk_pop" href="#sickle.REF.debaun.2014.699">DeBaun et al 2014</a>, <a class="bk_pop" href="#sickle.REF.estcourt.2017.cd012389">Estcourt et al 2017</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Priapism.</b> Episodes of severe priapism require urgent evaluation and treatment, including hydration and analgesia, and may require aspiration and irrigation by an urologist.</div></li></ul></div><div id="sickle.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p><b>Ongoing education</b> is essential to help minimize morbidity and mortality. Education comprises a regular review of interventions including the following:</p><ul><li class="half_rhythm"><div>Maintaining hydration and avoiding extremes of climate</div></li><li class="half_rhythm"><div>Monitoring for signs and symptoms requiring acute medical intervention</div></li><li class="half_rhythm"><div>Early detection of chronic complications</div></li><li class="half_rhythm"><div>Updates on new therapies</div></li></ul><p><b>Disease-modulating therapies</b> are discussed in several reviews [<a class="bk_pop" href="#sickle.REF.vichinsky.2012">Vichinsky 2012</a>, <a class="bk_pop" href="#sickle.REF.kassim.2013.451">Kassim &#x00026; DeBaun 2013</a>, <a class="bk_pop" href="#sickle.REF.ware.2017.311">Ware et al 2017</a>].</p><p><b>Chronic red blood cell transfusion therapy.</b> The initial goal of chronic red blood cell transfusion therapy varies depending on indication but typically is to maintain the percentage of HbS &#x0003c;30% and suppress reticulocytosis. Chronic red blood cell transfusion therapy may be warranted for the following [<a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>, Howard 2016, <a class="bk_pop" href="#sickle.REF.ware.2017.311">Ware et al 2017</a>]:</p><ul><li class="half_rhythm"><div>Primary prevention of stroke in individuals with an abnormal transcranial Doppler</div></li><li class="half_rhythm"><div>Prevention of stroke recurrence</div></li><li class="half_rhythm"><div>Treatment of chronic pain refractory to other therapies</div></li><li class="half_rhythm"><div>Pulmonary hypertension</div></li><li class="half_rhythm"><div>Chronic renal failure</div></li><li class="half_rhythm"><div>Recurrent episodes of ACS</div></li><li class="half_rhythm"><div>Severe end-organ damage</div></li></ul><p>Complications of chronic red blood cell transfusion therapy include: iron overload, alloimmunization, and, rarely, infection. To limit alloimmunization and transfusion reactions, extended matching of red blood cell antigens should be performed and blood products should be leuko-reduced (removal of white blood cells from the transfusion product). Red blood cells antigen matched at the full Rh <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> (D, C, E) and Kell have been suggested to decrease alloimmunization rates, as well as other alleles when possible [<a class="bk_pop" href="#sickle.REF.lasallewilliams.2011.1732">Lasalle-Williams et al 2011</a>]. Approaches to decrease alloimmunization in the future include obtaining a better understanding of the process of alloimmunization as well as molecular <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a>. Defining antigens molecularly has multiple benefits including the ability to type cells when serologic reagents are not available [<a class="bk_pop" href="#sickle.REF.yazdanbakhsh.2012.528">Yazdanbakhsh et al 2012</a>, <a class="bk_pop" href="#sickle.REF.matteocci.2014.197">Matteocci &#x00026; Pierelli 2014</a>].</p><p><b>Hydroxycarbamide (hydroxyurea),</b> until recently the only FDA-approved therapy for SCD, is only approved for adults. Hydroxyurea benefits individuals with SCD via several mechanisms [<a class="bk_pop" href="#sickle.REF.platt.2008.1362">Platt 2008</a>, <a class="bk_pop" href="#sickle.REF.ware.2010.5300">Ware 2010</a>] including:</p><ul><li class="half_rhythm"><div>Induction of HbF synthesis resulting in decreased sickling and improved red-cell survival;</div></li><li class="half_rhythm"><div>Reduction of white blood cell (WBC), reticulocyte and platelet counts;</div></li><li class="half_rhythm"><div>Metabolism into nitric oxide, a potent vasodilator;</div></li><li class="half_rhythm"><div>Overall improvement in blood flow;</div></li><li class="half_rhythm"><div>Reduction of vascular inflammation.</div></li></ul><p>Multiple NIH consensus statements have noted strong evidence to support its routine use in adults [<a class="bk_pop" href="#sickle.REF.brawley.2008.932">Brawley et al 2008</a>, <a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>]. It has been demonstrated that hydroxyurea therapy is safe to use in children as young as nine months with no decrease in immune function [<a class="bk_pop" href="#sickle.REF.ware.2010.5300">Ware 2010</a>, <a class="bk_pop" href="#sickle.REF.rogers.2011.2614">Rogers et al 2011</a>, <a class="bk_pop" href="#sickle.REF.wang.2011.1663">Wang et al 2011</a>, <a class="bk_pop" href="#sickle.REF.strouse.2012.365">Strouse &#x00026; Heeney 2012</a>, <a class="bk_pop" href="#sickle.REF.lederman.2014.686">Lederman et al 2014</a>]. It is now very strongly recommended that every individual with S/S and S/&#x003b2;<sup>0</sup>-thalassemia age nine months or older be offered treatment with hydroxyurea [<a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>]. This early initiation decreases clinical events [<a class="bk_pop" href="#sickle.REF.thornburg.2012.4304">Thornburg et al 2012</a>]. In addition, use of hydroxyurea has been associated with a decrease in healthcare costs [<a class="bk_pop" href="#sickle.REF.wang.2013.677">Wang et al 2013</a>].</p><p>Hydroxyurea can have potentially significant toxicity, including myelosuppression. Individuals treated with hydroxyurea must be monitored closely with CBCs and reticulocyte counts. In order to balance the benefits with potential toxicities of hydroxyurea, many suggest a careful titration of the drug to find a dosing for each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> person that provides an appropriate reduction in WBC count without toxicity [<a class="bk_pop" href="#sickle.REF.ware.2010.5300">Ware 2010</a>, <a class="bk_pop" href="#sickle.REF.strouse.2012.365">Strouse &#x00026; Heeney 2012</a>, <a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>].</p><p><b>Glutamine</b> has just received FDA approval for the prevention of acute complications in individuals age five years and older with SCD, whether on hydroxyurea or not. Due to its antioxidant properties and in vitro activity, glutamine has long been considered of potential benefit in the treatment of SCD. Though not published, a multicenter placebo-controlled clinical trial suggests that chronic use of oral glutamine can decrease the frequency of sickle cell pain-related episodes (<a href="https://clinicaltrials.gov/ct2/show/NCT01179217" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">clinicaltrials.gov/ct2/show/NCT01179217</a>). Having a second FDA-approved drug opens the door to combination therapy using multiple agents.</p><p><b>Stem cell transplantation</b> from a healthy donor or one with sickle cell trait can be curative in individuals with SCD and while the number of matched-sib transplants continues to rise, there is rapid evolution in the use of alternate donors. Children with SCD receiving stem cell transplantation using a matched sib donor can expect a 92% chance of cure with an overall survival of 95%. [<a class="bk_pop" href="#sickle.REF.king.2014.3089">King &#x00026; Shenoy 2014</a>, <a class="bk_pop" href="#sickle.REF.nickel.2014.861">Nickel et al 2014</a>, <a class="bk_pop" href="#sickle.REF.walters.2015.227">Walters 2015</a>]. These phenomenal outcomes are balanced by potential long-term consequences including chronic-graft-versus host disease and infertility. There is debate now as to who should be transplanted and when. Transplanting with a matched sib early in life can subvert a life of debilitating complications and decreasing end-organ function &#x02013; the latter making transplant at a later age more difficult. Notably, pediatric providers may overly worry about the risks of transplant, while not appreciating the high morbidity of sickle cell disease manifestations in adulthood. However, the comparative long-term benefits of supportive care (including hydroxyurea and improvements in sickle cell management) versus transplantation are not yet known.</p><p>Despite the great successes associated with transplantation, it is estimated that fewer than 30% of individuals with SCD have suitable matched-sib donors, few have suitable matched unrelated donors, and transplant for adults with SCD has been far more difficult due to regime-related toxicity. The field of transplantation for SCD is currently undergoing rapid expansion. Thus, the use of alternate donors (including unrelated donors and haploidentical donors) and cord blood is an active area of research [<a class="bk_pop" href="#sickle.REF.alfraih.2016.120">Alfraih et al 2016</a>, <a class="bk_pop" href="#sickle.REF.arnold.2016.515">Arnold et al 2016</a>, <a class="bk_pop" href="#sickle.REF.walters.2016.207">Walters et al 2016</a>].</p><p>Initial myeloablative regimes yielded too much toxicity for older individuals with SCD; the recent development of less toxic transplant regimens makes stem cell transplantation a more acceptable option for older individuals [<a class="bk_pop" href="#sickle.REF.tisdale.2013.s6">Tisdale et al 2013</a>].</p><p>While unrelated cord blood transplants are falling out of favor due to the high rate of graft failure, there is an increased use and success of haploidentical transplants, vastly broadening the number of individuals who could potentially be cured [<a class="bk_pop" href="#sickle.REF.gluckman.2013">Gluckman 2013</a>, <a class="bk_pop" href="#sickle.REF.tisdale.2013.s6">Tisdale et al 2013</a>, <a class="bk_pop" href="#sickle.REF.walters.2015.227">Walters 2015</a>, <a class="bk_pop" href="#sickle.REF.alfraih.2016.120">Alfraih et al 2016</a>, <a class="bk_pop" href="#sickle.REF.arnold.2016.515">Arnold et al 2016</a>].</p><p><b>Gene therapy.</b> As all allogenic transplants for SCD present a risk for graft-versus-host disease, there has been an explosion of research in <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> for SCD. While both gene editing and gene addition approaches are being activity pursued, only viral mediated gene therapy approaches are being used in clinical trials [<a class="bk_pop" href="#sickle.REF.goodman.2016.302">Goodman &#x00026; Malik 2016</a>, <a class="bk_pop" href="#sickle.REF.cavazzana.2017.1142">Cavazzana et al 2017</a>].</p><p>The criteria, risks, and benefits of transplantation are changing rapidly; thus, it is important for families and providers to discuss the risks and benefits with a transplantation center with expertise in SCD.</p></div><div id="sickle.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p><b>Newborn screening</b> has made presymptomatic diagnosis possible, allowing for early, aggressive education on management issues, such as management of fevers. The use of prophylactic penicillin, immunization, and education emphasizing access to healthcare have significantly decreased morbidity and mortality in children, primarily by reducing deaths from sepsis.</p><p><b>Penicillin prophylaxis</b> prevents 84% of life-threatening episodes of childhood <i>Streptococcus pneumoniae</i> sepsis [<a class="bk_pop" href="#sickle.REF.gaston.1986.1593">Gaston et al 1986</a>]:</p><ul><li class="half_rhythm"><div>By age two months, all infants with SCD should receive penicillin V potassium prophylaxis, 125 mg orally, twice a day.</div></li><li class="half_rhythm"><div>At age three years, the dose is increased to 250 mg orally, twice a day, and then continued until at least age five years.</div></li></ul><p><b>Prophylaxis for those allergic to penicillin</b> can include erythromycin or azithromycin but care should be taken to avoid medications that alter metabolism and increase the risk of prolonged QTc syndrome [<a class="bk_pop" href="#sickle.REF.gerber.2009.1541">Gerber et al 2009</a>].</p><p><b>Immunizations.</b> Timely administration of vaccines is essential. Clinicians should follow the recommended vaccine schedule for functionally asplenic individuals, which includes additional vaccines such as the 23-valent pneumococcal polysaccharide vaccine, and an altered schedule for meningococcal vaccines. Persons with sickle cell are considered high priority for annual influenza vaccine [<a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>].</p><p><b>Folic acid supplementation</b> should be considered to support the increased RBC synthesis secondary to the high RBC turnover in sickle cell.</p><p><b>Iron overload</b>. Individuals receiving prophylactic as well as chronic transfusions are at risk for iron overload and should be monitored closely, initially by tracking the amount of blood transfused and monitoring serum ferritin concentration. Those with high exposures or documented iron overload should have an assessment of organ iron accumulation. With its increasing availability and safety and the ability to assess iron in multiple organs while avoiding sampling bias, quantitative radiographic evaluation such as T<sub>2</sub>*-weighted MRI is increasingly replacing biopsy [<a class="bk_pop" href="#sickle.REF.wood.2007.183">Wood 2007</a>]. The noninvasive nature of monitoring iron overload via MRI or SQUID has led to significant improvements in the outcome of individuals with iron overload [<a class="bk_pop" href="#sickle.REF.coates.2014.23">Coates 2014</a>]. Both oral or subcutaneous iron chelation therapy are recommended for those with documented excessive tissue iron deposition, with patient acceptance and use of medications being the main limiting factor [<a class="bk_pop" href="#sickle.REF.coates.2017.703">Coates &#x00026; Wood 2017</a>].</p></div><div id="sickle.Surveillance"><h3>Surveillance</h3><p>Surveillance should be tailored to an individual's specific <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and clinical history; however, most individuals benefit from routine age-dependent screening to allow for early detection and treatment of end-organ damage [<a class="bk_pop" href="#sickle.REF94">NHS 2010</a>, <a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>]. The following are general guidelines compiled from several sources. Recently NHLBI has released updated guidelines that readers are encouraged to review. See <a href="#sickle.References">Published Guidelines/Consensus Statements</a>.</p><p><b>Comprehensive medical and social evaluation.</b> Affected individuals should be seen routinely for evaluation of risks, review of care plan, education, and assessment of growth and development. Social work assessment with emphasis on support, resources, and the impact of disease on lifestyle should be performed. Routine dental care is recommended.</p><p><b>Mental health and neurocognitive assessment.</b> Periodic mental health screening for signs of depression, anxiety, and isolation should occur. Neurocognitive testing should be performed prior to school entry and repeated periodically to identify learning difficulties that may be related to silent cerebral infarcts as well as other factors.</p><p><b>Annual laboratory assessment</b> should include the following:</p><ul><li class="half_rhythm"><div>CBC with differential and reticulocyte count</div></li><li class="half_rhythm"><div>Assessment of iron status</div></li><li class="half_rhythm"><div>Liver function tests (LFTs), BUN, serum creatinine, and urinalysis (UA)</div></li><li class="half_rhythm"><div>LDH as a marker of hemolysis</div></li><li class="half_rhythm"><div>Vitamin D level; may be indicated because of the high prevalence of deficiencies in this population</div></li></ul><p><b>Baseline values</b> should be given to parents for comparison during times of illness.</p><p><b>Extended red cell phenotyping</b> should be done once to decrease risk of alloimmunization with transfusions.</p><p><b>Assessment of stroke risk.</b> Historically more than 10% of young children with Hb S/S and Hb S/&#x003b2;&#x000b0;-thalassemia (as well as some others) had overt strokes. Yearly screening with transcranial Doppler (TCD) starting at age two years followed by initiation of chronic therapy for those with high-velocity blood flow has drastically decreased stroke incidence in SCD [<a class="bk_pop" href="#sickle.REF.fullerton.2004.336">Fullerton et al 2004</a>]. Individuals with an abnormally high arterial blood flow velocity have a high rate of stroke, which can be prevented by chronic red blood cell transfusion therapy. Children with normal velocities require yearly reevaluation as a proportion of them convert to higher-risk velocities over time [<a class="bk_pop" href="#sickle.REF.adams.2004.3689">Adams et al 2004</a>]. Initial studies suggest that this approach is decreasing the incidence of overt stroke in individuals with SCD, but additional measure may be of benefit as well [<a class="bk_pop" href="#sickle.REF.fullerton.2004.336">Fullerton et al 2004</a>, <a class="bk_pop" href="#sickle.REF.jordan.2012.14">Jordan et al 2012</a>, <a class="bk_pop" href="#sickle.REF.webb.2013.301">Webb &#x00026; Kwiatkowski 2013</a>].</p><p><b>End-organ evaluation.</b> While there is a clear consensus for use of screening TCD starting at age two years through at least age 16 years, there is variability in recommendations for additional screening. The NHLBI [<a class="bk_pop" href="#sickle.REF.yawn.2014.1033">Yawn et al 2014</a>] suggests screening for a proliferative retinopathy by an ophthalmologist starting age ten years, and additional screening based on clinical history that may include:</p><ul><li class="half_rhythm"><div>Chest x-ray examination</div></li><li class="half_rhythm"><div>ECG</div></li><li class="half_rhythm"><div>Pulmonary function tests (PFTs)</div></li><li class="half_rhythm"><div>Abdominal ultrasound examination</div></li><li class="half_rhythm"><div>Echocardiogram to determine the tricuspid regurgitant (TR) jet with consideration of right heart catheterization depending on symptoms</div></li><li class="half_rhythm"><div>Six-minute walk test</div></li><li class="half_rhythm"><div>Pulmonary function testing</div></li><li class="half_rhythm"><div>Sleep study (to assess nighttime hypoxemia)</div></li><li class="half_rhythm"><div>Iron overload by MRI</div></li></ul></div><div id="sickle.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Education for individuals with SCD involves learning how to control one's environment to minimize the chance of exacerbations. Environmental controls include avoiding the following:</p><ul><li class="half_rhythm"><div>Dehydration</div></li><li class="half_rhythm"><div>Extremes of temperature (e.g., swimming in cold water, which can trigger a pain episode)</div></li><li class="half_rhythm"><div>Physical exhaustion</div></li><li class="half_rhythm"><div>Extremely high altitude without oxygen supplementation</div></li><li class="half_rhythm"><div>Cocaine. While alcohol and illegal drugs are never endorsed, cocaine and its derivatives, with their vasoconstrictive and cardiac stimulation effects, are particularly dangerous drugs in the setting of SCD.</div></li><li class="half_rhythm"><div>The analgesic meperidine, which should be avoided as first-line therapy because of potential CNS toxicity</div></li></ul></div><div id="sickle.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Early diagnosis of at-risk family members may allow intervention before symptoms are present.</p><p>If born in the United States, sibs <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with SCD are diagnosed by universal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> soon after birth (at which time referral to a pediatric hematologist is appropriate). Many states also identify sickle cell trait on newborn screening.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> data is not available for at-risk sibs, several diagnostic approaches can be considered.</p><ul><li class="half_rhythm"><div>If the <i>HBB</i> pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk sibs.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known, the gold standard is a combination of HPLC or <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> combined with a CBC and reticulocyte count. As microcytosis helps guide interpretation of results, a measure of iron status such as a ZPP (zinc protoporphyrin) test or serum iron and TIBC (total iron binding capacity) is of benefit.</div></li></ul><p>See <a href="#sickle.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="sickle.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy complications in SCD can be minimized with close follow up and collaboration between hematology and obstetric teams [<a class="bk_pop" href="#sickle.REF.naik.2012">Naik &#x00026; Lanzkron 2012</a>]. Pregnancy in women with SCD involves increased risk for thrombosis, infectious complications, and acute painful episodes [<a class="bk_pop" href="#sickle.REF.villers.2008.125.e1">Villers et al 2008</a>, <a class="bk_pop" href="#sickle.REF.naik.2012">Naik &#x00026; Lanzkron 2012</a>, <a class="bk_pop" href="#sickle.REF.alayed.2014.487">Alayed et al 2014</a>, <a class="bk_pop" href="#sickle.REF.costa.2015.685">Costa et al 2015</a>]. There is conflicting information as to whether the risks for preeclampsia, eclampsia, pre-term labor, and maternal death are increased [<a class="bk_pop" href="#sickle.REF.villers.2008.125.e1">Villers et al 2008</a>, <a class="bk_pop" href="#sickle.REF.naik.2012">Naik &#x00026; Lanzkron 2012</a>, <a class="bk_pop" href="#sickle.REF.alayed.2014.487">Alayed et al 2014</a>, <a class="bk_pop" href="#sickle.REF.costa.2015.685">Costa et al 2015</a>]. The risk of pregnancy complications increases when access to prenatal care is limited, reinforcing the importance of close hematologic and obstetric follow up [<a class="bk_pop" href="#sickle.REF.naik.2012">Naik &#x00026; Lanzkron 2012</a>]. The benefits of a chronic transfusion program versus the use of "as-needed" transfusions has not been established [<a class="bk_pop" href="#sickle.REF.okusanya.2016.cd010378">Okusanya and Oladapo 2016</a>]. As hydroxyurea is recommended for (and increasingly used in) adults, the current recommendation is that it be discontinued during pregnancy. While reports of human infants exposed prenatally to hydroxyurea have not noted an increased risk of malformations, in experimental animal models hydroxyurea has been noted to lead to an increase in <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies. The role of chronic transfusions in lieu of hydroxyurea needs to be addressed.</p><p>More than 99% of births to women with SCD occurring after 28 weeks&#x02019; gestation are live births with normal Apgar scores [<a class="bk_pop" href="#sickle.REF.smith.1996.199">Smith et al 1996</a>]. Several studies have reported increased rates of low birth weight and intrauterine growth retardation in babies born to women with SCD [<a class="bk_pop" href="#sickle.REF.hassell.2005.903">Hassell 2005</a>]. Attention to postnatal opiate withdrawal in the babies of mothers treated with high-dose opiates during pregnancy is warranted.</p><p>Infants with SCD are asymptomatic in the antenatal, perinatal, and immediate postnatal periods; they manifest disease symptoms when fetal hemoglobin production switches to adult hemoglobin.</p></div><div id="sickle.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Currently only one drug &#x02013; hydroxyurea &#x02013; is FDA approved for SCD, and labeling does not include children. After decades of slow progress in the field, acknowledgment of the plethora of pathways modulating the severity of SCD has led to a diverse array of therapeutic agents that are being investigated [<a class="bk_pop" href="#sickle.REF.archer.2015.934">Archer et al 2015</a>, <a class="bk_pop" href="#sickle.REF.kato.2016.224">Kato 2016</a>].</p><p>Some examples emphasizing the diverse array of involved pathways and agents are listed below. The field is changing rapidly; refer to <a href="https://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for the status of current studies.</p><p><b>Prevention of HbS polymerization.</b> Hemoglobin S polymerizes in the T (tense) conformation associated with de-oxygenation, but not the R (relaxed) conformation associated with oxygenation. Thus, small molecules that block the T-state or stabilize the R-state are being assessed in clinical trials [<a class="bk_pop" href="#sickle.REF.oder.2016.24">Oder et al 2016</a>].</p><p><b>Decreasing adhesion to the endothelium.</b> Adhesion of WBC to the endothelium of the microcirculation slows blood flow, increasing HbS polymerization and worsening SCD. Agents that decrease cell adherence without compromising immune function are being pursued. E- and P-selectin specific agents are being tested with one showing promising results in a Phase III trial [<a class="bk_pop" href="#sickle.REF.zhang.2016.801">Zhang et al 2016</a>, <a class="bk_pop" href="#sickle.REF.ataga.2017.429">Ataga et al 2017</a>].</p><ul><li class="half_rhythm"><div><b>Modifying inflammatory responses.</b> Regadenoson is an adenosine A2A receptor agonist that modifies natural killer cell activity and has shown benefit in animal models. It has been evaluated in a Phase I study and a Phase II clinical trial is under way [<a class="bk_pop" href="#sickle.REF.field.2013.3329">Field et al 2013</a>].</div></li><li class="half_rhythm"><div><b>Antioxidants therapy.</b> Multiple antioxidants are being studied. One, glutamine, is a key factor in determining red cell red-ox state and its level has been a marker of disease severity [<a class="bk_pop" href="#sickle.REF.morris.2008b.402">Morris et al 2008b</a>]. Results for a Phase III clinical trial of glutamine supplementation are pending.</div></li><li class="half_rhythm"><div><b>Rejuvenation of nitric oxide (NO) stores.</b> Arginine, the precursor of NO, has been studied in several contexts and a Phase II clinical trial has shown benefit in hospitalized people with sickle cell pain [<a class="bk_pop" href="#sickle.REF.morris.2013.1375">Morris et al 2013</a>]. As a result, arginine has been featured in multiple clinical trials.</div></li><li class="half_rhythm"><div><b>Induction of fetal hemoglobin.</b> Multiple pathways and factors associated with the high-level expression of the fetal hemoglobin genes (<i>HBG1</i> and <i>HBG2</i>) have been identified and are currently targets for intervention [<a class="bk_pop" href="#sickle.REF.perrine.2014.233">Perrine et al 2014</a>, <a class="bk_pop" href="#sickle.REF.lettre.2016.2554">Lettre &#x00026; Bauer 2016</a>]. Representative pathways include LSD-1 inhibitors [<a class="bk_pop" href="#sickle.REF.shi.2013.291">Shi et al 2013</a>, <a class="bk_pop" href="#sickle.REF.cui.2015.386">Cui et al 2015</a>], thalidomide inhibitors (e.g., pomolidomide) [<a class="bk_pop" href="#sickle.REF.dulmovits.2016.1481">Dulmovits et al 2016</a>], nuclear factor erythroid 2-related factor 2 inhibitors (e.g., tert-butylhydroquinone) [<a class="bk_pop" href="#sickle.REF.macari.2011.5987">Macari &#x00026; Lowrey 2011</a>, <a class="bk_pop" href="#sickle.REF.macari.2013.830">Macari et al 2013</a>], HDAC inhibitors [<a class="bk_pop" href="#sickle.REF.okam.2012.303">Okam &#x00026; Ebert 2012</a>], short-chain fatty acids (e.g., butyrate or valproic acid), and antimetabolites (e.g., 2&#x02019; deoxy 5&#x02019; azacytidine [decitabine]) [<a class="bk_pop" href="#sickle.REF.saunthararajah.2008.126">Saunthararajah et al 2008</a>]. A promising approach to therapy is the development of inhibitors to the protein Bcl11a. Bcl11a was identified as an HbF cell quantitative trait <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> in a genome-wide association study [<a class="bk_pop" href="#sickle.REF.menzel.2007.1197">Menzel et al 2007</a>]. Since then it has been shown to bind within the &#x003b2;-globin locus and to be critical for suppressing fetal globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression in adult erythroid cells [<a class="bk_pop" href="#sickle.REF.sankaran.2008.1839">Sankaran et al 2008</a>, <a class="bk_pop" href="#sickle.REF.sankaran.2010.64">Sankaran et al 2010</a>]. Knockdown or knockout of Bcl11a in model systems, as well as naturally occurring deletions that remove its binding site in humans, result in substantial increases in HbF. These elevated levels of HbF provide therapeutic benefits to individuals with both SCD and thalassemia [<a class="bk_pop" href="#sickle.REF.sankaran.2011.807">Sankaran et al 2011</a>, <a class="bk_pop" href="#sickle.REF.wilber.2011.2817">Wilber et al 2011</a>, <a class="bk_pop" href="#sickle.REF.xu.2011.993">Xu et al 2011</a>]. Multiple approaches are being taken to inhibit Bcl11a function in vivo, including gene editing to disrupt the erythroid-specific enhancer of Bcl11a [<a class="bk_pop" href="#sickle.REF.lettre.2016.2554">Lettre &#x00026; Bauer 2016</a>].</div></li><li class="half_rhythm"><div><b>Phytomedicines</b>, including some mixtures of plants, are under investigation. There are initial promising safety and efficacy data for Niprisan<sup>&#x000ae;</sup> and SCD-101 [<a class="bk_pop" href="#sickle.REF.oniyangi.2015.cd004448">Oniyangi &#x00026; Cohall 2015</a>].</div></li></ul><p><b>Gene therapy.</b> As SCD arises from a defined single-nucleotide substitution in the &#x003b2;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> whose expression is restricted to erythroid cells derived from bone marrow hematopoietic stem cells, SCD is an ideal candidate for <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>. Gene therapy provides the benefit of stem cell transplantation, but without the problems associated with the use of an allogenic source of stem cells. Ideally, gene therapy would lead to an increase in non-sickle &#x003b2;-like chains, while lowering the number of sickle chains, for example by replacing the HbS <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Glu6Val) with a normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p><p>The most progress has been made using viral vector-mediated addition of a normal &#x003b2;-like <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, potentially modified to have additional anti-sickling properties. This leaves the endogenous sickle <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> intact. While multiple groups are moving towards these gene addition clinical trials, to date only one individual is reported to have been cured [<a class="bk_pop" href="#sickle.REF.cavazzana.2017.1142">Cavazzana et al 2017</a>, <a class="bk_pop" href="#sickle.REF.ribeil.2017.848">Ribeil et al 2017</a>]. The status of these trials is changing rapidly; refer to <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for the most up-to-date information.</p><p>Multiple <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> strategies that do not involve the addition of an additional, therapeutic globin gene are being pursued. A major obstacle to the above gene addition approaches is the requirement for long-term, high-level expression of the therapeutic gene, which requires the inclusion of large amounts of the major regulatory element, the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> control region. In contrast, these approaches involve the transduction and stable integration of therapeutic reagent for which low-level expression suffices. These include:</p><ul><li class="half_rhythm"><div>Using transactivators to stimulate the minimally expressed delta <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or the fetal or embryonic genes;</div></li><li class="half_rhythm"><div>Inducing embryonic &#x003b1;-like chains that, when forming tetramers with sickle chains, are less likely to polymerize;</div></li><li class="half_rhythm"><div>Decreasing <i>Bcl11a</i> expression whether by knocking out erythroid regulatory elements or binding sites, knocking down <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>, or altering protein interactions; and</div></li><li class="half_rhythm"><div>Inducing "looping" between the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> control region and the fetal globin genes resulting in activation of HbF.</div></li></ul><p>Some of the above approaches have the additional benefit of reducing expression of the sickle <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> while increasing expression of a therapeutic gene. However, they require long-term expression, typically from a viral vector integrated into the genome, leading to the very real risk of severe sequelae, such as leukemia, stemming from insertional mutagenesis [<a class="bk_pop" href="#sickle.REF.cavazza.2013.119">Cavazza et al 2013</a>]. These detriments of routine <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> are avoided by "gene editing." As multiple techniques to modify the human genome with <a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> accuracy are becoming increasingly easy and efficient, gene editing approaches are being aggressively pursued [<a class="bk_pop" href="#sickle.REF.scharenberg.2013.291">Scharenberg et al 2013</a>, <a class="bk_pop" href="#sickle.REF.kim.2014.321">Kim &#x00026; Kim 2014</a>]. Gene editing typically entails the generation of a break in the DNA at or near the site of interest and the presence of a "corrective template." Fortuitously, the cell&#x02019;s endogenous DNA repair machinery inadvertently uses the therapeutic template when repairing the DNA, resulting in the incorporation of the corrective sequence. Gene editing is a "hit and run" approach, as it can be performed with the transient expression of the editing tools, thus avoiding the need for long-term expression as well as the risk for insertional mutagenesis, yet providing lifelong correction of the DNA. Two major approaches are being taken: removal of the sickle <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and replacement with a normal sequence; and disruption of regulators of globin gene expression &#x02013; such as Bcl11a, which in turn results in increased expression of the fetal genes. As this can be done in hematopoietic as well as induced pleuripotent stem cells, gene editing is the future of gene therapy.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="sickle.Genetic_Counseling"><h2 id="_sickle_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="sickle.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Sickle cell disease (SCD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="sickle.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The parents of an individual with Hb S/S are typically heterozygotes (i.e., carriers of at least one HbS <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div><div class="half_rhythm">It is possible that a parent is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> (i.e., Hb S/S) or is a compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (e.g., Hb S/&#x003b2;&#x000b0;-thalassemia) rather than a heterozygote (Hb A/S).</div></li><li class="half_rhythm"><div class="half_rhythm">The parents of an individual who is a compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (e.g., Hb S/C or Hb S/&#x003b2;&#x000b0;-thalassemia) are typically <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>; one parent for HbS, and one parent for the other <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Heterozygotes (carriers) are generally asymptomatic, but may develop complications under extremes of physical exertion, dehydration, and/or altitude. There is increasing awareness of the risk for impaired renal concentrating abilities and microhematuria as well as an increased risk for venous thromboembolism in carriers of HbS as well as splenic infarcts, or sudden death associated with extreme conditions.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>If both parents are carriers of an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has, at conception, a 25% chance of being affected, a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>If one parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with SCD (i.e., is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) and the other parent is heterozygous for an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each sib of an affected individual has a 50% chance of being affected and a 50% chance of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>If both parents are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with SCD (i.e., both parents are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>), all sibs of an affected individual will be affected.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are generally asymptomatic, but may develop complications under extremes of physical exertion, dehydration, and/or altitude. There is increasing awareness of the risk for complications such as impaired renal concentrating abilities and microhematuria, and increased risk for venous thromboembolism in carriers of HbS as well as splenic infarcts, or sudden death associated with extreme conditions.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with SCD are obligate heterozygotes (carriers) for an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for HbS or another sickle cell <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each offspring will be at a 50% risk of having SCD.</div></li><li class="half_rhythm"><div>If the reproductive partner of an individual with SCD is also <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with SCD, all offspring will have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HBB</i> pathogenic variants; the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in these individuals will depend on their specific <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (see <a href="#sickle.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</div></li></ul><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% or greater risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an SCD-related <i>HBB</i> variant.</div></li><li class="half_rhythm"><div>If one sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, each other (unaffected) sib of the proband's parent is at a 67% (2/3) risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li></ul></div><div id="sickle.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>If both SCD-related <i>HBB</i> pathogenic variants in a family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to identify which at-risk family members are carriers.</p><p>If only one (or neither) SCD-related <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a family is known, HPLC can be used to detect common <i>HBB</i> pathogenic variants involving qualitative abnormalities (i.e., abnormal hemoglobins). Note that HPLC may not always detect quantitative abnormalities such as thalassemias, which, when inherited with an HbS <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, result in a significant hemoglobinopathy; see <a href="/books/n/gene/b-thal/">Beta-Thalassemia</a> for information on how to diagnose a coexisting thalassemia. Typical parental genotypes are described in <a class="figpopup" href="/books/NBK1377/table/sickle.T.sickle_cell_disease_parent_and/?report=objectonly" target="object" rid-figpopup="figsickleTsicklecelldiseaseparentand" rid-ob="figobsickleTsicklecelldiseaseparentand">Table 3</a>.</p><div id="sickle.T.sickle_cell_disease_parent_and" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Sickle Cell Disease: Parent and Proband Abnormal Globin &#x003b2;-Chain Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.T.sickle_cell_disease_parent_and/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.T.sickle_cell_disease_parent_and_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" style="text-align:left;vertical-align:middle;">Abnormal Globin &#x003b2;-Chain Variants of the Proband</th><th id="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Typical Parental Globin &#x003b2;-Chain Variants&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2" id="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">One Parent</th><th headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2" id="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Parent</th></tr></thead><tbody><tr><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/S</td><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2 hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">A/S</td><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2 hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A/S</td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/&#x003b2;&#x000b0;-thal&#x000a0;<sup>2</sup></td><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2 hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">A<br />&#x02193;MCV<br />N or &#x02191;HbA<sub>2</sub><br />N or &#x02191;HbF</td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/&#x003b2;+-thal&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">S/C</td><td headers="hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_1_2 hd_h_sickle.T.sickle_cell_disease_parent_and_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">A/C</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Table shows typical results; exceptions occur. Some rare globin &#x003b2; chain variants (e.g., S/D, S/O<sup>Arab</sup>, S/C<sup>Harlem</sup>, Hb Lepore, S/E) are not included.</p></div></dd><dt></dt><dd><div><p class="no_margin">thal = thalassemia</p></div></dd><dt></dt><dd><div><p class="no_margin">MCV = mean corpuscular volume</p></div></dd><dt></dt><dd><div><p class="no_margin">N = normal</p></div></dd><dt></dt><dd><div><p class="no_margin">&#x02191;= increased</p></div></dd><dt></dt><dd><div><p class="no_margin">&#x02193;= decreased</p></div></dd><dt>1. </dt><dd><div id="sickle.TF.3.1"><p class="no_margin">Assumes that <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> is absent and that both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>. Some parents may be <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>.</p></div></dd><dt>2. </dt><dd><div id="sickle.TF.3.2"><p class="no_margin">HbA is detectable in individuals with &#x003b2;+-thalassemia but not S/&#x003b2;<sup>0</sup>-thalassemia or Hb S/C.</p></div></dd></dl></div></div></div></div><div id="sickle.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#sickle.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>It must be kept in mind that non-sickle &#x003b2;-globin disorders (e.g., <a href="/books/n/gene/b-thal/">&#x003b2;-thalassemia</a>) can interact with the SCD-causing variant to cause clinically significant disease. As a result, family members without HbS can still have a child with a significant sickle hemoglobinopathy, which makes counseling difficult and leads to misconceptions in the community, and, on occasion, allegations of infidelity. For example, if one parent has sickle cell trait and the other has &#x003b2;-thalassemia trait, it would be correct to state that, although one parent is not a sickle cell <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, there is still a 25% chance that each pregnancy would have a significant hemoglobinopathy. Therefore, partners of individuals who are known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for HbS should be offered a thalassemia screening panel that includes hemoglobin electrophoresis, CBC and reticulocyte count, and a measure of iron status (e.g., ZPP or serum iron and TIBC) to screen for carrier status for sickle cell trait and other &#x003b2;-globin disorders.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>Early testing.</b> Building community awareness of SCD in populations at high risk is an important component in facilitating early testing and receiving <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p><p><b>Cord blood banking.</b> Given the (1) increasing safety and availability of stem cell transplantation in SCD and (2) limited number of immunologically matched donors available for individuals with SCD, it is appropriate to discuss sib cord blood banking with the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Though it will not alter the diagnosis, consideration can be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals as it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future (allowing better understanding of risk and modifying loci).</p></div><div id="sickle.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>HBB</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for pregnancies at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for SCD are possible.</p><p>Because one parent may have a non-HbS <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that can interact with HbS to cause a sickle hemoglobinopathy (e.g., HbC or Hb &#x003b2;-thalassemia), both disease-causing <i>HBB</i> alleles of the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> parents must be identified before prenatal testing can be performed.</p><p>Note: Because of the large variation in clinical course, currently it is not possible to accurately predict the severity of SCD in an individual.</p><p>When the mother is a known <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> and the father is unknown and/or unavailable for testing, options for prenatal testing can be explored in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p></div></div><div id="sickle.Resources"><h2 id="_sickle_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>About Sickle Cell Disease</b></div><div><a href="http://www.sicklecellinfo.net" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sicklecellinfo.net</a></div></li><li class="half_rhythm"><div><b>American Sickle Cell Anemia Association</b></div><div>10300 Carnegie Avenue</div><div>Cleveland OH 44106</div><div><b>Phone:</b> 216-229-8600</div><div><b>Fax:</b> 216-229-4500</div><div><b>Email:</b> irabragg@ascaa.org</div><div><a href="http://www.ascaa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ascaa.org</a></div></li><li class="half_rhythm"><div><b>California Sickle Cell Resources</b></div><div><a href="http://casicklecell.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.casicklecell.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Sickle%20cell%20disease&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sickle cell disease</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/ghr/disease/sicklecellanemia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sickle Cell Disease</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22238/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sickle Cell Disease</a></div></li><li class="half_rhythm"><div><b>Save Babies Through Screening Foundation, Inc.</b></div><div>P. O. Box 42197</div><div>Cincinnati OH 45242</div><div><b>Phone:</b> 888-454-3383</div><div><b>Email:</b> email@savebabies.org</div><div><a href="http://www.savebabies.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.savebabies.org</a></div></li><li class="half_rhythm"><div><b>Sickle Cell Adult Provider Network</b></div><div><a href="http://www.ucdenver.edu/academics/colleges/medicalschool/centers/sicklecell/SCAPN/Pages/SCAPNHome.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCAPN</a></div></li><li class="half_rhythm"><div><b>Sickle Cell Disease Association of America, Inc. (SCDAA)</b></div><div>231 East Baltimore Street</div><div>Suite 800</div><div>Baltimore MD 21202</div><div><b>Phone:</b> 800-421-8453 (toll-free); 410-528-1555</div><div><b>Fax:</b> 410-528-1495</div><div><b>Email:</b> scdaa@sicklecelldisease.org</div><div><a href="http://www.sicklecelldisease.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sicklecelldisease.org</a></div></li><li class="half_rhythm"><div><b>Sickle Cell Disease Foundation of California</b></div><div>5777 West Century Boulevard</div><div>Suite 1230</div><div>Los Angeles CA 90045</div><div><b>Phone:</b> 310-693-0247</div><div><b>Fax:</b> 310-216-0307</div><div><b>Email:</b> info@scdfc.org</div><div><a href="http://www.scdfc.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.scdfc.org</a></div></li><li class="half_rhythm"><div><b>Sickle Cell Disease National Resource Directory</b></div><div><a href="https://www.cdc.gov/ncbddd/sicklecell/map/text-nationalresourcedirectory.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cdc.gov/ncbddd/sicklecell</a></div></li><li class="half_rhythm"><div><b>Sickle Cell Information Center</b></div><div><a href="http://scinfo.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.scinfo.org</a></div></li><li class="half_rhythm"><div><b>National Newborn Screening and Global Resource Center</b></div><div><a href="http://genes-r-us.uthscsa.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.genes-r-us.uthscsa.edu</a></div></li><li class="half_rhythm"><div><b>National Haemoglobinopathy Registry</b></div><div>MDSAS NHR Administrator</div><div>5 Union Street</div><div>City View House</div><div> Manchester M12 4JD</div><div>United Kingdom</div><div><b>Phone:</b> 0161 277 7917</div><div><b>Email:</b> support@mdsas.com</div><div><a href="http://www.nhr.nhs.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nhr.nhs.uk</a></div></li></ul></div><div id="sickle.Molecular_Genetics"><h2 id="_sickle_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="sickle.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Sickle Cell Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_sickle.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_sickle.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_sickle.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_sickle.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_sickle.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_sickle.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_sickle.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3043" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HBB</i></a></td><td headers="hd_b_sickle.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3043" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11p15<wbr style="display:inline-block"></wbr>​.4</a></td><td headers="hd_b_sickle.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P68871" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemoglobin subunit beta</a></td><td headers="hd_b_sickle.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HBB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB @ LOVD</a><br /><a href="http://globin.cse.psu.edu/globin/hbvar/menu.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HbVar: A Database of Human Hemoglobin Variants and Thalassemias (HBB)</a></td><td headers="hd_b_sickle.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HBB" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB</a></td><td headers="hd_b_sickle.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HBB[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBB</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="sickle.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="sickle.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Sickle Cell Disease (<a href="/omim/141900,603903" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/141900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">141900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOGLOBIN--BETA LOCUS; HBB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603903" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603903</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SICKLE CELL ANEMIA</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>HBB</i>, which spans 1.6 kb, contains three exons. <i>HBB</i> is regulated by an adjacent 5' promoter, which contains TATA, CAAT, and duplicated CACCC boxes, and an upstream regulatory element known as the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> control region (LCR). <i>HBB</i> is contained within the <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster, which also includes the genes encoding the delta-globin chain, A gamma and G gamma chains, and <i>HBBP1</i> (an <i>HBB</i> <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>) and epsilon. For a detailed summary of gene and protein information, see <a href="/books/NBK1377/#sickle.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Sickle cell disease results from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>HBB</i> pathogenic variants where at least one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is the p.Glu6Val <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (e.g., <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> p.Glu6Val; p.Glu6Val and a second <i>HBB</i> pathogenic variant &#x02013; see <a class="figpopup" href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figsickleThbbpathogenicvariantsdiscuss" rid-ob="figobsickleThbbpathogenicvariantsdiscuss">Table 4</a> for examples).</p><div id="sickle.T.hbb_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>HBB</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1377/table/sickle.T.hbb_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sickle.T.hbb_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change&#x000a0;<sup>1</sup></th><th id="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Standard Nomenclature&#x000a0;<sup>2</sup>)</th><th id="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb Variant</th><th id="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.20A&#x0003e;T</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu6Val<br />(p.Glu7Val)</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbS</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_4" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000518.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000518<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?val=NP_000509.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000509<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.19G&#x0003e;A</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu6Lys<br />(p.Glu7Lys)</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbC</td></tr><tr><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.79G&#x0003e;A</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu26Lys<br />(p.Glu27Lys)</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbE</td></tr><tr><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.364G&#x0003e;C</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu121Gln<br />(p.Glu122Gln)</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbD-Punjab</td></tr><tr><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.364G&#x0003e;A</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu121Lys<br />(p.Glu122Lys)</td><td headers="hd_h_sickle.T.hbb_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbO-Arab</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="sickle.TF.4.1"><p class="no_margin">DNA nucleotide changes follow current nomenclature guidelines where the number 1 corresponds to the first nucleotide of the initiating methionine.</p></div></dd><dt>2. </dt><dd><div id="sickle.TF.4.2"><p class="no_margin">In this column and throughout the text of the <i>GeneReview</i>, the protein amino acid changes (e.g., p.Glu6Val) follow the long-standing convention in the hemoglobin literature to begin numbering the amino acids at the second amino acid residue (Val) rather than the initiating Met. This convention was adopted many years ago because the initiating methionine is not part of the mature &#x003b2;-globin protein. The standard nomenclature for protein changes are given in parentheses. The Globin Gene Server (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin<wbr style="display:inline-block"></wbr>​.cse.psu.edu</a>) lists variants using both numbering conventions.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>HBB</i> encodes the hemoglobin &#x003b2; chain. The normal heterotetrameric protein hemoglobin A (HbA) comprises two hemoglobin &#x003b1; chains, two hemoglobin &#x003b2; chains, and four heme moieties.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Sickle hemoglobin (HbS) results specifically from the p.Glu6Val substitution. In deoxygenated sickle hemoglobin, an interaction between p.Val6 and the complementary regions on adjacent molecules results in the formation of highly ordered, insoluble molecular polymers that aggregate and distort the shape of red blood cells, making them brittle and poorly deformable, increasing adherence to the endothelium. This can lead to veno-occlusion, decreased tissue perfusion, and ischemia. While this is thought to be the proximate defect leading to several aspects of clinical disease, there is increasing awareness that multiple pathophysiologic pathways are involved in SCD [<a class="bk_pop" href="#sickle.REF.zhang.2016.801">Zhang et al 2016</a>, <a class="bk_pop" href="#sickle.REF.kato.2017.750">Kato et al 2017</a>].</p><p>Polymerized hemoglobin is also injurious to the red cell membrane, resulting in cellular dehydration, oxidative damage, and increased adherence to endothelial cells [<a class="bk_pop" href="#sickle.REF.gladwin.2000.1476">Gladwin &#x00026; Rodgers 2000</a>, <a class="bk_pop" href="#sickle.REF.hebbel.2000.1910">Hebbel 2000</a>, <a class="bk_pop" href="#sickle.REF.nagel.2001.105">Nagel 2001</a>] and chronic hemolysis.</p><p>Other factors contributing to the pathophysiology of sickle cell include: leukocytosis (resulting in increased production of injurious cytokines and altered blood flow), coagulation abnormalities, and abnormal vascular regulation. The net result of these abnormalities is shortened red cell life span or hemolysis and intermittent vascular occlusion and a state of chronic inflammation.</p></div><div id="sickle.References"><h2 id="_sickle_References_">References</h2><div id="sickle.Published_GuidelinesConsensus_Sta"><h3>Published Guidelines/Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sickle.REF1">National Health Service. NHS Sickle Cell &#x00026; Thalassaemia Screening Programme. Standards and Guidelines. Available <a href="http://sct.screening.nhs.uk/standardsandguidelines" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 3-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF2">National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. Available <a href="https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2014. Accessed 3-20-18.</div></li></ul></div><div id="sickle.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.adamkiewicz.2003.438">Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. <span><span class="ref-journal">J Pediatr. </span>2003;<span class="ref-vol">143</span>:438–44.</span> [<a href="/pubmed/14571216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14571216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.adams.2005.2769">Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">353</span>:2769–78.</span> [<a href="/pubmed/16382063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16382063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.adams.2004.3689">Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, Pegelow CH, Woods G, Rohde EM, Nichols FT, Jones A, Luden JP, Bowman L, Hagner S, Morales KH, Roach ES, et al.  Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:3689–94.</span> [<a href="/pubmed/14751925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14751925</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.adams.1998.5">Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">339</span>:5–11.</span> [<a href="/pubmed/9647873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9647873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.adeyoju.2002.898">Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. <span><span class="ref-journal">BJU Int. </span>2002;<span class="ref-vol">90</span>:898–902.</span> [<a href="/pubmed/12460353" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12460353</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.alayed.2014.487">Alayed N, Kezouh A, Oddy L, Abenhaim HA. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. <span><span class="ref-journal">J Perinat Med. </span>2014;<span class="ref-vol">42</span>:487–92.</span> [<a href="/pubmed/24344096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24344096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.alfraih.2016.120">Alfraih F, Aljurf M, Fitzhugh CD, Kassim AA. Alternative donor allogeneic hematopoietic cell transplantation for hemoglobinopathies. <span><span class="ref-journal">Semin Hematol. </span>2016;<span class="ref-vol">53</span>:120–8.</span> [<a href="/pubmed/27000737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27000737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.aliyu.2008.63">Aliyu ZY, Kato GJ, Taylor J 6th, Babadoko A, Mamman AI, Gordeuk VR, Gladwin MT. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. <span><span class="ref-journal">Am J Hematol. </span>2008;<span class="ref-vol">83</span>:63–70.</span> [<a href="/pubmed/17910044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17910044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.aloe.2011.337">Aloe A, Krishnamurti L, Kladny B. Testing of collegiate athletes for sickle cell trait: what we, as genetic counselors should know. <span><span class="ref-journal">J Genet Couns. </span>2011;<span class="ref-vol">20</span>:337–40.</span> [<a href="/pubmed/21503822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21503822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.archer.2015.934">Archer N, Galacteros F, Brugnara C. 2015 Clinical trials update in sickle cell anemia. <span><span class="ref-journal">Am J Hematol. </span>2015;<span class="ref-vol">90</span>:934–50.</span> [<a href="/pmc/articles/PMC5752136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5752136</span></a>] [<a href="/pubmed/26178236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26178236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.arkuszewski.2014.108">Arkuszewski M, Krejza J, Chen R, Ichord R, Kwiatkowski JL, Bilello M, Zimmerman R, Ohene-Frempong K, Melhem ER. Sickle cell anemia: intracranial stenosis and silent cerebral infarcts in children with low risk of stroke. <span><span class="ref-journal">Adv Med Sci. </span>2014;<span class="ref-vol">59</span>:108–13.</span> [<a href="/pubmed/24797985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24797985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.arnold.2016.515">Arnold SD, Bhatia M, Horan J, Krishnamurti L. Haematopoietic stem cell transplantation for sickle cell disease: current practice and new approaches. <span><span class="ref-journal">Br J Haematol. </span>2016;<span class="ref-vol">174</span>:515–25.</span> [<a href="/pubmed/27255787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27255787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ataga.2017.429">Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">376</span>:429–39.</span> [<a href="/pmc/articles/PMC5481200/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5481200</span></a>] [<a href="/pubmed/27959701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27959701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.austin.2007.908">Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC. Sickle cell trait and the risk of venous thromboembolism among blacks. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:908–12.</span> [<a href="/pubmed/17409269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17409269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.bakanay.2005.545">Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. Mortality in sickle cell patients on hydroxyurea therapy. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:545–7.</span> [<a href="/pubmed/15454485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15454485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.baskin.2013.1035">Baskin MN, Goh XL, Heeney MM, Harper MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. <span><span class="ref-journal">Pediatrics. </span>2013;<span class="ref-vol">131</span>:1035–41.</span> [<a href="/pubmed/23669523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23669523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.bender.2012">Bender MA, Seibel G. Sickle cell disease critical elements of care. The Center for Children with Special Needs. Seattle Children&#x02019;s Hospital, Seattle, WA. Available <a href="http://cshcn.org/wp-content/uploads/files/CriticalElementsofCare-SickleCell.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 3-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.bernaudin.2011.1130">Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Co&#x000ef;c L, Leveill&#x000e9; E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galact&#x000e9;ros F, Torres M, Kuentz M, Ferry C, Soci&#x000e9; G, Reinert P, Delacourt C. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:1130–40.</span> [<a href="/pubmed/21068435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21068435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.bonham.2010.997">Bonham VL, Dover GJ, Brody LC. Screening student athletes for sickle cell trait--a social and clinical experiment. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:997–9.</span> [<a href="/pubmed/20825310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20825310</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.brawley.2008.932">Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. <span><span class="ref-journal">Ann Intern Med. </span>2008;<span class="ref-vol">148</span>:932–8.</span> [<a href="/pubmed/18458271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18458271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.brousse.2014.g1765">Brousse V, Makani J, Rees DC. Management of sickle cell disease in the community. <span><span class="ref-journal">BMJ. </span>2014;<span class="ref-vol">348</span>:g1765.</span> [<a href="/pmc/articles/PMC5612384/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5612384</span></a>] [<a href="/pubmed/24613806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24613806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.cavazza.2013.119">Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and mutagenesis. <span><span class="ref-journal">Hum Gene Ther. </span>2013;<span class="ref-vol">24</span>:119–31.</span> [<a href="/pubmed/23330935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23330935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.cavazzana.2017.1142">Cavazzana M, Antoniani C, Miccio A. Gene Therapy for &#x003b2;-Hemoglobinopathies. <span><span class="ref-journal">Mol Ther. </span>2017;<span class="ref-vol">25</span>:1142–54.</span> [<a href="/pmc/articles/PMC5417842/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5417842</span></a>] [<a href="/pubmed/28377044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28377044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.chulamokha.2006.723">Chulamokha L, Scholand SJ, Riggio JM, Ballas SK, Horn D, DeSimone JA. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. <span><span class="ref-journal">Am J Hematol. </span>2006;<span class="ref-vol">81</span>:723–8.</span> [<a href="/pubmed/16795063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16795063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.coates.2014.23">Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. <span><span class="ref-journal">Free Radic Biol Med. </span>2014;<span class="ref-vol">72</span>:23–40.</span> [<a href="/pmc/articles/PMC4940047/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4940047</span></a>] [<a href="/pubmed/24726864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24726864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.coates.2017.703">Coates TD, Wood JC. How we manage iron overload in sickle cell patients. <span><span class="ref-journal">Br J Haematol. </span>2017;<span class="ref-vol">177</span>:703–16.</span> [<a href="/pmc/articles/PMC5444974/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5444974</span></a>] [<a href="/pubmed/28295188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28295188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.costa.2015.685">Costa VM, Viana MB, Aguiar RA. Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes. <span><span class="ref-journal">J Matern Fetal Neonatal Med. </span>2015;<span class="ref-vol">28</span>:685–9.</span> [<a href="/pubmed/24866352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24866352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.cui.2015.386">Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>:386–96.</span> [<a href="/pmc/articles/PMC4504950/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4504950</span></a>] [<a href="/pubmed/26031919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26031919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.darbari.2012.286">Darbari DS, Onyekwere O, Nouraie M, Minniti CP, Luchtman-Jones L, Rana S, Sable C, Ensing G, Dham N, Campbell A, Arteta M, Gladwin MT, Castro O, Taylor JG 6th, Kato GJ, Gordeuk V. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. <span><span class="ref-journal">J Pediatr. </span>2012;<span class="ref-vol">160</span>:286–90.</span> [<a href="/pmc/articles/PMC3258348/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3258348</span></a>] [<a href="/pubmed/21890147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21890147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.debaun.2014.699">DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">371</span>:699–710.</span> [<a href="/pmc/articles/PMC4195437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4195437</span></a>] [<a href="/pubmed/25140956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25140956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.debaun.2016.829">DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:829–38.</span> [<a href="/pubmed/26758917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26758917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.de_castro.2008.19">De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. <span><span class="ref-journal">Am J Hematol. </span>2008;<span class="ref-vol">83</span>:19–25.</span> [<a href="/pubmed/17724699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17724699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.de_montalembert.2012.3870">de Montalembert M. To SWiTCH or not to SWiTCH? <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>:3870–1.</span> [<a href="/pubmed/22538492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22538492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.dulmovits.2016.1481">Dulmovits BM, Appiah-Kubi AO, Papoin J, Hale J, He M, Al-Abed Y, Didier S, Gould M, Husain-Krautter S, Singh SA, Chan KW, Vlachos A, Allen SL, Taylor N, Marambaud P, An X, Gallagher PG, Mohandas N, Lipton JM, Liu JM, Blanc L. Pomalidomide reverses &#x003b3;-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:1481–92.</span> [<a href="/pmc/articles/PMC4797024/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4797024</span></a>] [<a href="/pubmed/26679864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26679864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ellison.2015.423">Ellison AM, Thurm C, Alessandrini E, Jain S, Cheng J, Black K, Schroeder L, Stone K, Alpern ER. Variation in pediatric emergency department care of sickle cell disease and fever. <span><span class="ref-journal">Acad Emerg Med. </span>2015;<span class="ref-vol">22</span>:423–30.</span> [<a href="/pubmed/25779022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25779022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.estcourt.2017.cd012389">Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2017;<span class="ref-vol">5</span>:CD012389.</span> [<a href="/pmc/articles/PMC5460750/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5460750</span></a>] [<a href="/pubmed/28500860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28500860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.field.2013.3329">Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:3329–34.</span> [<a href="/pmc/articles/PMC3637009/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3637009</span></a>] [<a href="/pubmed/23377438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23377438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.fitzhugh.2010.36">Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X, Wright EC, Gilliam FR, De Castro LM. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. <span><span class="ref-journal">Am J Hematol. </span>2010;<span class="ref-vol">85</span>:36–40.</span> [<a href="/pmc/articles/PMC3865703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3865703</span></a>] [<a href="/pubmed/20029950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.fullerton.2004.336">Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>:336–9.</span> [<a href="/pubmed/15054044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15054044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.gaston.1986.1593">Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Tate Holbrook C, Gill FM, Ritchey K, Falletta JM., Prophylactic Penicillin Study Group.  Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">314</span>:1593–9.</span> [<a href="/pubmed/3086721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3086721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.gerber.2009.1541">Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <span><span class="ref-journal">Circulation. </span>2009;<span class="ref-vol">119</span>:1541–51.</span> [<a href="/pubmed/19246689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19246689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.gill.1995.776">Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. <span><span class="ref-journal">Blood. </span>1995;<span class="ref-vol">86</span>:776–83.</span> [<a href="/pubmed/7606007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7606007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.gladwin.2000.1476">Gladwin MT, Rodgers GP. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. <span><span class="ref-journal">Lancet. </span>2000;<span class="ref-vol">355</span>:1476–8.</span> [<a href="/pubmed/10801164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10801164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.gluckman.2013">Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:370-6. [<a href="/pubmed/24319206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24319206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.goldsmith.2012.340">Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. <span><span class="ref-journal">Am J Hematol. </span>2012;<span class="ref-vol">87</span>:340–6.</span> [<a href="/pmc/articles/PMC3513289/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3513289</span></a>] [<a href="/pubmed/22307997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22307997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.goodman.2016.302">Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. <span><span class="ref-journal">Ther Adv Hematol. </span>2016;<span class="ref-vol">7</span>:302–15.</span> [<a href="/pmc/articles/PMC5026290/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5026290</span></a>] [<a href="/pubmed/27695619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27695619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.harteveld.2005.922">Harteveld CL, Voskamp A, Phylipsen M, Akkermans N, den Dunnen JT, White SJ, Giordano PC. Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:922–31.</span> [<a href="/pmc/articles/PMC1735959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735959</span></a>] [<a href="/pubmed/15894596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15894596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hassell.2005.903">Hassell K. Pregnancy and sickle cell disease. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2005;<span class="ref-vol">19</span>:903–16.</span> [<a href="/pubmed/16214651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16214651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hassell.2010.s512">Hassell KL. Population estimates of sickle cell disease in the U.S. <span><span class="ref-journal">Am J Prev Med. </span>2010;<span class="ref-vol">38</span>:S512–21.</span> [<a href="/pubmed/20331952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20331952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hassell.2014.237">Hassell KL, Afenyi-Annan A, Ballas SK, Buchanan GR, Eckman JR, Jordan L, Lanzkron S, Lottenberg R, Ware R. Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2014;<span class="ref-vol">190</span>:237–8.</span> [<a href="/pubmed/25025359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25025359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hebbel.2000.1910">Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:1910–2.</span> [<a href="/pubmed/10861330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10861330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hebbel.2011.123">Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. <span><span class="ref-journal">Am J Hematol. </span>2011;<span class="ref-vol">86</span>:123–54.</span> [<a href="/pubmed/21264896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21264896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.hebson.2015.134">Hebson C, New T, Record E, Oster M, Ehrlich A, Border W, James-Herry A, Kanaan U. Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought? <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2015;<span class="ref-vol">37</span>:134–9.</span> [<a href="/pubmed/24942020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24942020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF56">Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016;2016:625-31. [<a href="/pmc/articles/PMC6142434/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6142434</span></a>] [<a href="/pubmed/27913538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27913538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.jordan.2012.14">Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. <span><span class="ref-journal">Br J Haematol. </span>2012;<span class="ref-vol">157</span>:14–25.</span> [<a href="/pmc/articles/PMC3400704/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3400704</span></a>] [<a href="/pubmed/22224940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22224940</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kassim.2013.451">Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. <span><span class="ref-journal">Annu Rev Med. </span>2013;<span class="ref-vol">64</span>:451–66.</span> [<a href="/pubmed/23190149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23190149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kato.2016.224">Kato GJ. New insights into sickle cell disease: mechanisms and investigational therapies. <span><span class="ref-journal">Curr Opin Hematol. </span>2016;<span class="ref-vol">23</span>:224–32.</span> [<a href="/pmc/articles/PMC4969007/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4969007</span></a>] [<a href="/pubmed/27055046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27055046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kato.2006.2279">Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">107</span>:2279–85.</span> [<a href="/pmc/articles/PMC1895723/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1895723</span></a>] [<a href="/pubmed/16291595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16291595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kato.2017.750">Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. <span><span class="ref-journal">J Clin Invest. </span>2017;<span class="ref-vol">127</span>:750–60.</span> [<a href="/pmc/articles/PMC5330745/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5330745</span></a>] [<a href="/pubmed/28248201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28248201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kato.2010.690">Kato GJ, Taylor JG 6th. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">148</span>:690–701.</span> [<a href="/pmc/articles/PMC3210728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3210728</span></a>] [<a href="/pubmed/19958359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19958359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.key.2010.418">Key NS, Derebail VK. Sickle-cell trait: novel clinical significance. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2010;<span class="ref-vol">2010</span>:418–22.</span> [<a href="/pmc/articles/PMC3299004/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3299004</span></a>] [<a href="/pubmed/21239829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21239829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kim.2014.321">Kim H, Kim JS. A guide to genome engineering with programmable nucleases. <span><span class="ref-journal">Nat Rev Genet. </span>2014;<span class="ref-vol">15</span>:321–34.</span> [<a href="/pubmed/24690881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24690881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.king.2014.3089">King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:3089–94.</span> [<a href="/pubmed/24511087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24511087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.klings.2014a.238">Klings ES, Machado RF, Morris CR, Gordeuk VR, Kato GJ, Ataga KI, Castro O, Hsu L, Telen MJ, Krishnamurti L, Steinberg MH, Gladwin MT., ATS Clinical Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease Committee.  Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2014a;<span class="ref-vol">190</span>:238–40.</span> [<a href="/pmc/articles/PMC4226058/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4226058</span></a>] [<a href="/pubmed/25025360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25025360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.klings.2014b.2881">Klings ES, Morris CR, Hsu LL, Castro O, Gladwin MT, Mubarak KK. Pulmonary hypertension of sickle cell disease beyond classification constraints. <span><span class="ref-journal">J Am Coll Cardiol. </span>2014b;<span class="ref-vol">63</span>:2881–2.</span> [<a href="/pubmed/24794120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24794120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.kushner.2001.47">Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2001:47–61.</span> [<a href="/pubmed/11722978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11722978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.lasallewilliams.2011.1732">Lasalle-Williams M, Nuss R, Le T, Cole L, Hassell K, Murphy JR, Ambruso DR. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). <span><span class="ref-journal">Transfusion. </span>2011;<span class="ref-vol">51</span>:1732–9.</span> [<a href="/pubmed/21332724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21332724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.lederman.2014.686">Lederman HM, Connolly MA, Kalpatthi R, Ware RE, Wang WC, Luchtman-Jones L, Waclawiw M, Goldsmith JC, Swift A, Casella JF, et al.  Immunologic effects of hydroxyurea in sickle cell anemia. <span><span class="ref-journal">Pediatrics. </span>2014;<span class="ref-vol">134</span>:686–95.</span> [<a href="/pmc/articles/PMC4179098/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4179098</span></a>] [<a href="/pubmed/25180279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25180279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.lee.2009.437">Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">146</span>:437–41.</span> [<a href="/pmc/articles/PMC3078564/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3078564</span></a>] [<a href="/pubmed/19563512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19563512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.lettre.2016.2554">Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. <span><span class="ref-journal">Lancet. </span>2016;<span class="ref-vol">387</span>:2554–64.</span> [<a href="/pubmed/27353686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27353686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.liem.2009.645">Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA. Functional capacity in children and young adults with sickle cell disease undergoing evaluation for cardiopulmonary disease. <span><span class="ref-journal">Am J Hematol. </span>2009;<span class="ref-vol">84</span>:645–9.</span> [<a href="/pubmed/19705433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19705433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.macari.2011.5987">Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:5987–97.</span> [<a href="/pmc/articles/PMC3112042/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3112042</span></a>] [<a href="/pubmed/21464371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21464371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.macari.2013.830">Macari ER, Schaeffer EK, West RJ, Lowrey CH. Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:830–9.</span> [<a href="/pmc/articles/PMC3563366/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3563366</span></a>] [<a href="/pubmed/23223429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23223429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.machado.2006.310">Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT, Investigators MSH. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. <span><span class="ref-journal">JAMA. </span>2006;<span class="ref-vol">296</span>:310–8.</span> [<a href="/pubmed/16849664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16849664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.manci.2003.359">Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN., Investigators of the Cooperative Study of Sickle Cell Disease.  Causes of death in sickle cell disease: an autopsy study. <span><span class="ref-journal">Br J Haematol. </span>2003;<span class="ref-vol">123</span>:359–65.</span> [<a href="/pubmed/14531921" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14531921</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.matteocci.2014.197">Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. <span><span class="ref-journal">Vox Sang. </span>2014;<span class="ref-vol">106</span>:197–208.</span> [<a href="/pubmed/24117723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24117723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.mekontso_dessap.2011.1022">Mekontso Dessap A, Deux JF, Abidi N, Lavenu-Bombled C, Melica G, Renaud B, Godeau B, Adnot S, Brochard L, Brun-Buisson C, Galacteros F, Rahmouni A, Habibi A, Maitre B. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2011;<span class="ref-vol">184</span>:1022–9.</span> [<a href="/pubmed/21836136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21836136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.menzel.2007.1197">Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelenika D, Boland A, Rooks H, Best S, Spector TD, Farrall M, Lathrop M, Thein SL. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:1197–9.</span> [<a href="/pubmed/17767159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17767159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.miller.2011.5297">Miller ST. How I treat acute chest syndrome in children with sickle cell disease. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:5297–305.</span> [<a href="/pubmed/21406723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21406723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.miller.2000.83">Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. Prediction of adverse outcomes in children with sickle cell disease. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:83–9.</span> [<a href="/pubmed/10631276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10631276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.miller.2001.785">Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ. STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">139</span>:785–9.</span> [<a href="/pubmed/11743502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11743502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.mitchell.2007.300">Mitchell BL. Sickle cell trait and sudden death--bringing it home. <span><span class="ref-journal">J Natl Med Assoc. </span>2007;<span class="ref-vol">99</span>:300–5.</span> [<a href="/pmc/articles/PMC2569637/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2569637</span></a>] [<a href="/pubmed/17393956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17393956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.morris.1999.64">Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? <span><span class="ref-journal">Ann Emerg Med. </span>1999;<span class="ref-vol">34</span>:64–9.</span> [<a href="/pubmed/10381996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10381996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.morris.2011.1">Morris CR. Vascular risk assessment in patients with sickle cell disease. <span><span class="ref-journal">Haematologica. </span>2011;<span class="ref-vol">96</span>:1–5.</span> [<a href="/pmc/articles/PMC3012755/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3012755</span></a>] [<a href="/pubmed/21193426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21193426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.morris.2013.1375">Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, Gildengorin G, Neumayr L, Vichinsky EP. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. <span><span class="ref-journal">Haematologica. </span>2013;<span class="ref-vol">98</span>:1375–82.</span> [<a href="/pmc/articles/PMC3762093/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3762093</span></a>] [<a href="/pubmed/23645695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23645695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.morris.2008b.402">Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. <span><span class="ref-journal">Blood. </span>2008b;<span class="ref-vol">111</span>:402–10.</span> [<a href="/pmc/articles/PMC2200820/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2200820</span></a>] [<a href="/pubmed/17848621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17848621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.mousa.2010.291">Mousa SA, Qari MH. Diagnosis and management of sickle cell disorders. <span><span class="ref-journal">Methods Mol Biol. </span>2010;<span class="ref-vol">663</span>:291–307.</span> [<a href="/pubmed/20617425" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20617425</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.nagel.2001.105">Nagel RL. Pleiotropic and epistatic effects in sickle cell anemia. <span><span class="ref-journal">Curr Opin Hematol. </span>2001;<span class="ref-vol">8</span>:105–10.</span> [<a href="/pubmed/11224685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11224685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.naik.2017.2180">Naik RP, Irvin MR, Judd S, Guti&#x000e9;rrez OM, Zakai NA, Derebail VK, Peralta C, Lewis MR, Zhi D, Arnett D, McClellan W, Wilson JG, Reiner AP, Kopp JB, Winkler CA, Cushman M. Sickle cell trait and the risk of ESRD in blacks. <span><span class="ref-journal">J Am Soc Nephrol. </span>2017;<span class="ref-vol">28</span>:2180–7.</span> [<a href="/pmc/articles/PMC5491293/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5491293</span></a>] [<a href="/pubmed/28280138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28280138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.naik.2012">Naik RP, Lanzkron S. Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2012;2012:208-14. [<a href="/pubmed/23233583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23233583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.neville.2011">Neville KA, Panepinto JA. Pharmacotherapy of sickle cell disease. 18th Expert Committee on the Selection and Use of Essential Medicines. Available <a href="http://www.who.int/selection_medicines/committees/expert/18/applications/Sicklecell.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 3-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF94">NHS. Sickle cell disease in childhood: Standards and guidelines for clinical care (pdf). Available <a href="http://sct.screening.nhs.uk/getdata.php?id=11164" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 3-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.nickel.2014.861">Nickel RS, Hendrickson JE, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">124</span>:861–6.</span> [<a href="/pubmed/24963044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24963044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.oder.2016.24">Oder E, Safo MK, Abdulmalik O, Kato GJ. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? <span><span class="ref-journal">Br J Haematol. </span>2016;<span class="ref-vol">175</span>:24–30.</span> [<a href="/pmc/articles/PMC5035193/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5035193</span></a>] [<a href="/pubmed/27605087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27605087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.okam.2012.303">Okam MM, Ebert BL. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. <span><span class="ref-journal">Expert Rev Hematol. </span>2012;<span class="ref-vol">5</span>:303–11.</span> [<a href="/pubmed/22780210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22780210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.okusanya.2016.cd010378">Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2016;<span class="ref-vol">12</span>:CD010378.</span> [<a href="/pmc/articles/PMC6463955/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6463955</span></a>] [<a href="/pubmed/28005272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28005272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.oniyangi.2015.cd004448">Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2015;(4):CD004448.</span> [<a href="/pubmed/25844571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25844571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.parent.2011.44">Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Ya&#x000ef;ci A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G. A hemodynamic study of pulmonary hypertension in sickle cell disease. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:44–53.</span> [<a href="/pubmed/21732836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21732836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.perrine.2014.233">Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2014;<span class="ref-vol">28</span>:233–48.</span> [<a href="/pubmed/24589264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24589264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.platt.2008.1362">Platt OS. Hydroxyurea for the treatment of sickle cell anemia. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:1362–9.</span> [<a href="/pubmed/18367739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18367739</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.platt.1994.1639">Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. <span><span class="ref-journal">N Engl J Med. </span>1994;<span class="ref-vol">330</span>:1639–44.</span> [<a href="/pubmed/7993409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7993409</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.powars.2002.206">Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. <span><span class="ref-journal">Am J Hematol. </span>2002;<span class="ref-vol">70</span>:206–15.</span> [<a href="/pubmed/12111766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12111766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.quinn.2010.3447">Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:3447–52.</span> [<a href="/pmc/articles/PMC2867259/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2867259</span></a>] [<a href="/pubmed/20194891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20194891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ribeil.2017.848">Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chr&#x000e9;tien S, Lefebvre T, Ross RW, Negre O, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M. Gene therapy in a patient with sickle cell disease. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">376</span>:848–855.</span> [<a href="/pubmed/28249145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28249145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.rogers.2005.917">Rogers ZR. Priapism in sickle cell disease. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2005;<span class="ref-vol">19</span>:917–28.</span> [<a href="/pubmed/16214652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16214652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.rogers.2011.2614">Rogers ZR, Wang WC, Luo Z, Lyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2614–7.</span> [<a href="/pmc/articles/PMC3062353/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3062353</span></a>] [<a href="/pubmed/21217080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21217080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.sachdev.2011.1452">Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. Walk-PHASST Investigators. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. <span><span class="ref-journal">Circulation. </span>2011;<span class="ref-vol">124</span>:1452–60.</span> [<a href="/pmc/articles/PMC3183314/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3183314</span></a>] [<a href="/pubmed/21900080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21900080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.sankaran.2008.1839">Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. <span><span class="ref-journal">Science. </span>2008;<span class="ref-vol">322</span>:1839–42.</span> [<a href="/pubmed/19056937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19056937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.sankaran.2011.807">Sankaran VG, Xu J, Byron R, Greisman HA, Fisher C, Weatherall DJ, Sabath DE, Groudine M, Orkin SH, Premawardhena A, Bender MA. A functional element necessary for fetal hemoglobin silencing. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:807–14.</span> [<a href="/pmc/articles/PMC3174767/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3174767</span></a>] [<a href="/pubmed/21879898" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21879898</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.sankaran.2010.64">Sankaran VG, Xu J, Orkin SH. Transcriptional silencing of fetal hemoglobin by BCL11A. <span><span class="ref-journal">Ann N Y Acad Sci. </span>2010;<span class="ref-vol">1202</span>:64–8.</span> [<a href="/pubmed/20712774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20712774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.saunthararajah.2008.126">Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J. Clinical effectiveness of decitabine in severe sickle cell disease. <span><span class="ref-journal">Br J Haematol. </span>2008;<span class="ref-vol">141</span>:126–9.</span> [<a href="/pubmed/18324975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18324975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.scharenberg.2013.291">Scharenberg AM, Duchateau P, Smith J. Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies. <span><span class="ref-journal">Curr Gene Ther. </span>2013;<span class="ref-vol">13</span>:291–303.</span> [<a href="/pubmed/23888878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23888878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.schatz.2001.1109">Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:1109–11.</span> [<a href="/pubmed/11320190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11320190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.serjeant.2013.a011783">Serjeant GR. The natural history of sickle cell disease. <span><span class="ref-journal">Cold Spring Harb Perspect Med. </span>2013;<span class="ref-vol">3</span>:a011783.</span> [<a href="/pmc/articles/PMC3784812/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3784812</span></a>] [<a href="/pubmed/23813607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23813607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.shi.2013.291">Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. <span><span class="ref-journal">Nat Med. </span>2013;<span class="ref-vol">19</span>:291–4.</span> [<a href="/pmc/articles/PMC5512162/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5512162</span></a>] [<a href="/pubmed/23416702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23416702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.smith.1996.199">Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. <span><span class="ref-journal">Obstet Gynecol. </span>1996;<span class="ref-vol">87</span>:199–204.</span> [<a href="/pubmed/8559523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8559523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.steinberg.2005.465">Steinberg MH. Predicting clinical severity in sickle cell anaemia. <span><span class="ref-journal">Br J Haematol. </span>2005;<span class="ref-vol">129</span>:465–81.</span> [<a href="/pubmed/15877729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15877729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.steinberg.2006.131">Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. <span><span class="ref-journal">Curr Opin Hematol. </span>2006;<span class="ref-vol">13</span>:131–6.</span> [<a href="/pubmed/16567954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16567954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.strouse.2012.365">Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2012;<span class="ref-vol">59</span>:365–71.</span> [<a href="/pmc/articles/PMC3374046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3374046</span></a>] [<a href="/pubmed/22517797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22517797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.tarini.2012.446">Tarini BA, Brooks MA, Bundy DG. A policy impact analysis of the mandatory NCAA sickle cell trait screening program. <span><span class="ref-journal">Health Serv Res. </span>2012;<span class="ref-vol">47</span>:446–61.</span> [<a href="/pmc/articles/PMC3288389/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3288389</span></a>] [<a href="/pubmed/22150647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22150647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.thompson.2013">Thompson AA. Sickle cell trait testing and athletic participation: a solution in search of a problem? Hematology Am Soc Hematol Educ Program. 2013;2013:632-7. [<a href="/pubmed/24319243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24319243</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.thornburg.2012.4304">Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC, et al.  Impact of hydroxyurea on clinical events in the BABY HUG trial. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:4304–10.</span> [<a href="/pmc/articles/PMC3507142/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3507142</span></a>] [<a href="/pubmed/22915643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22915643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.tisdale.2013.s6">Tisdale JF, Eapen M, Saccardi R. HCT for nonmalignant disorders. <span><span class="ref-journal">Biol Blood Marrow Transplant. </span>2013;<span class="ref-vol">19</span>:S6–9.</span> [<a href="/pubmed/23104188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23104188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.vichinsky.2012">Vichinsky E. Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology Am Soc Hematol Educ Program. 2012;2012:271-5. [<a href="/pubmed/23233591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23233591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.vichinsky.1990.1617">Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. <span><span class="ref-journal">N Engl J Med. </span>1990;<span class="ref-vol">322</span>:1617–21.</span> [<a href="/pubmed/2342522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2342522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.villers.2008.125.e1">Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2008;<span class="ref-vol">199</span>:125.e1–5.</span> [<a href="/pubmed/18533123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18533123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.walters.2015.227">Walters MC. Update of hematopoietic cell transplantation for sickle cell disease. <span><span class="ref-journal">Curr Opin Hematol. </span>2015;<span class="ref-vol">22</span>:227–33.</span> [<a href="/pmc/articles/PMC5037959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5037959</span></a>] [<a href="/pubmed/25767957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25767957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.walters.2016.207">Walters MC, De Castro LM, Sullivan KM, Krishnamurti L, Kamani N, Bredeson C, Neuberg D, Hassell KL, Farnia S, Campbell A, Petersdorf E. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. <span><span class="ref-journal">Biol Blood Marrow Transplant. </span>2016;<span class="ref-vol">22</span>:207–11.</span> [<a href="/pmc/articles/PMC5031360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5031360</span></a>] [<a href="/pubmed/26500093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26500093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wang.2000.335">Wang WC, Gallagher DM, Pegelow CH, Wright EC, Vichinsky EP, Abboud MR, Moser FG, Adams RJ. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2000;<span class="ref-vol">22</span>:335–9.</span> [<a href="/pubmed/10959904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10959904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wang.2013.677">Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD, et al.  Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. <span><span class="ref-journal">Pediatrics. </span>2013;<span class="ref-vol">132</span>:677–83.</span> [<a href="/pmc/articles/PMC4074648/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4074648</span></a>] [<a href="/pubmed/23999955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23999955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wang.2011.1663">Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW., BABY HUG investigators.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">377</span>:1663–72.</span> [<a href="/pmc/articles/PMC3133619/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3133619</span></a>] [<a href="/pubmed/21571150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21571150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ware.2010.5300">Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:5300–11.</span> [<a href="/pmc/articles/PMC2902131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2902131</span></a>] [<a href="/pubmed/20223921" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20223921</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ware.2017.311">Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. <span><span class="ref-journal">Lancet. </span>2017;<span class="ref-vol">390</span>:311–323.</span> [<a href="/pubmed/28159390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28159390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.ware.2012.3925">Ware RE, Helms RW. SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>:3925–32.</span> [<a href="/pmc/articles/PMC3350359/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3350359</span></a>] [<a href="/pubmed/22318199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22318199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.webb.2013.301">Webb J, Kwiatkowski JL. Stroke in patients with sickle cell disease. <span><span class="ref-journal">Expert Rev Hematol. </span>2013;<span class="ref-vol">6</span>:301–16.</span> [<a href="/pubmed/23782084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23782084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wilber.2011.2817">Wilber A, Hargrove PW, Kim YS, Riberdy JM, Sankaran VG, Papanikolaou E, Georgomanoli M, Anagnou NP, Orkin SH, Nienhuis AW, Persons DA. Therapeutic levels of fetal hemoglobin in erythroid progeny of &#x003b2;-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2817–26.</span> [<a href="/pmc/articles/PMC3062294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3062294</span></a>] [<a href="/pubmed/21156846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21156846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wood.2012.123ra26">Wood DK, Soriano A, Mahadevan L, Higgins JM, Bhatia SN. A biophysical indicator of vaso-occlusive risk in sickle cell disease. <span><span class="ref-journal">Sci Transl Med. </span>2012;<span class="ref-vol">4</span>:123ra26.</span> [<a href="/pmc/articles/PMC3633235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3633235</span></a>] [<a href="/pubmed/22378926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22378926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.wood.2007.183">Wood JC. Magnetic resonance imaging measurement of iron overload. <span><span class="ref-journal">Curr Opin Hematol. </span>2007;<span class="ref-vol">14</span>:183–90.</span> [<a href="/pmc/articles/PMC2892972/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2892972</span></a>] [<a href="/pubmed/17414205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17414205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.xu.2011.993">Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, Tucker PW, Orkin SH. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. <span><span class="ref-journal">Science. </span>2011;<span class="ref-vol">334</span>:993–6.</span> [<a href="/pmc/articles/PMC3746545/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3746545</span></a>] [<a href="/pubmed/21998251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21998251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.yawn.2014.1033">Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease summary of the 2014 evidence-based report by expert panel members. <span><span class="ref-journal">JAMA. </span>2014;<span class="ref-vol">312</span>:1033–48.</span> [<a href="/pubmed/25203083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25203083</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.yazdanbakhsh.2012.528">Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:528–37.</span> [<a href="/pmc/articles/PMC3401213/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3401213</span></a>] [<a href="/pubmed/22563085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22563085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.zarrouk.2006.43">Zarrouk V, Habibi A, Zahar JR, Roudot-Thoraval F, Bachir D, Brun-Buisson C, Legrand P, Godeau B, Galacteros F, Lesprit P. Bloodstream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. <span><span class="ref-journal">Medicine (Baltimore). </span>2006;<span class="ref-vol">85</span>:43–8.</span> [<a href="/pubmed/16523052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16523052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sickle.REF.zhang.2016.801">Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:801–9.</span> [<a href="/pmc/articles/PMC4760086/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4760086</span></a>] [<a href="/pubmed/26758915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26758915</span></a>]</div></li></ul></div></div><div id="sickle.Chapter_Notes"><h2 id="_sickle_Chapter_Notes_">Chapter Notes</h2><div id="sickle.Author_History"><h3>Author History</h3><p>MA Bender, MD, PhD (2006-present)<br />Gabrielle Douthitt Seibel, MN, MPH, ARNP; Seattle Children&#x02019;s Hospital (2014-2017)<br />William Hobbs, MD, PhD; Puget Sound Blood Center (2009-2014)<br />Krysta Schlis, MD; Children's Hospital Oakland (2003-2006)<br />Elliott Vichinsky, MD; Children's Hospital Oakland (2003-2006)</p></div><div id="sickle.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 August 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 October 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 May 2012 (mb) Revision: clarification of information regarding risk for renal medullary carcinoma in individuals with sickle cell trait</div></li><li class="half_rhythm"><div>9 February 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 September 2009 (cd) Revision: corrections to testing information (<a class="figpopup" href="/books/NBK1377/table/sickle.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figsickleTmoleculargenetictestingused" rid-ob="figobsickleTmoleculargenetictestingused">Table 2</a>)</div></li><li class="half_rhythm"><div>6 August 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 March 2006 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>15 September 2003 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>21 April 2003 (ev) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1377</span><span class="label">PMID: <a href="/pubmed/20301551" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301551</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/sft/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rss/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1377&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1377/?report=reader">PubReader</a></li><li><a href="/books/NBK1377/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1377" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1377" style="display:none" title="Cite this Page"><div class="bk_tt">Bender MA. Sickle Cell Disease. 2003 Sep 15 [Updated 2017 Aug 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1377/pdf/Bookshelf_NBK1377.pdf">PDF version of this page</a> (609K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#sickle.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#sickle.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#sickle.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#sickle.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#sickle.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#sickle.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#sickle.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#sickle.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#sickle.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#sickle.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#sickle.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#sickle.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3043[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HBB</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1499456" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1499456" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1499456" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1499456" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301599" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301608" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R, Moi P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624460" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalfa TA, Connor JA, Begtrup AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30843001" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Sickle cell diseases: What can nuclear medicine offer?</a><span class="source">[Hell J Nucl Med. 2019]</span><div class="brieflinkpop offscreen_noflow">Sickle cell diseases: What can nuclear medicine offer?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Niccoli Asabella A, Altini C, Nappi AG, Lavelli V, Ferrari C, Marzullo A, Loiodice A, Rubini G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hell J Nucl Med. 2019 Jan-Apr; 22(1):2-3. Epub 2019 Mar 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28500860" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Interventions for preventing silent cerebral infarcts in people with sickle cell disease.</a><span class="source">[Cochrane Database Syst Rev. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Interventions for preventing silent cerebral infarcts in people with sickle cell disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2017 May 13; 5:CD012389. Epub 2017 May 13.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301551" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301551" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040edcdd21425a2572a80e">Sickle Cell Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Sickle Cell Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:37:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BB8DAE0405E01000000000385014E&amp;ncbi_session=CE8BB8DAE040EDC1_0901SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1377%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1377&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1377/&amp;ncbi_pagename=Sickle Cell Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BB8DAE040EDC1_0901SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>